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This thesis contains the findings from four years of research regarding an oligodendrocyte 
protein named neurofascin 155. The role of this protein in maintaining adhesion between 
the myelin sheath of oligodendrocytes and the axons of neurons has become well 
established in recent years and the research presented here has revealed that while western 
blots have previously shown one protein/band representing neurofascin 155, there are two 
proteins/bands. These two proteins have been named neurofascin 155 high and neurofascin 
155 low due to their previous inclusion in the single band. The work leading up to their 
discovery, findings, and the relevance of these two proteins will be discussed in animal 
models with disrupted myelin:axon adhesion and in the human disease multiple sclerosis. 
 1 
{CHAPTER 1 Introduction} 
 
“Animal electricity” 
Late in the eighteenth century Italian scientist Luigi Galvani inadvertently discovered the 
role of electricity in life (Piccollini, 2006). The leg of a dead frog was made to twitch and 
cramp upon addition of a piece of charged metal. Originally termed “animal electricity” 
and hotly debated as separate from metal-ion based electricity, this discovery led to the 
invention of the battery by Galvani’s colleague and intellectual rival Alessandro Volta. 
Follow up work has given us the understanding that animal, plant, and all other forms of 
electricity are the result of the same process; the directed motion of charged particles 
known as ions. 
 
In animals, the major source of electricity is neurons and the ion responsible for electrical 
conduction is sodium (Na
+
). Named for Latin and Greek terms referring to long, slender 
objects, neurons are cells that conduct electricity via action potentials to communicate with 
other cells, sometimes over enormous distances; up to 2.5 meters in the case of giraffes 
(Badlangana et al., 2007). Neurons in the vertebrate central nervous system (CNS), 
comprised of the brain, spinal cord, and optic nerves, use electricity to relay the presence 
or absence of stimulation. The stimulation and ultimate response to it are in the form of 
chemical signals called neurotransmitters, with some neurons releasing or being receptive 
to only certain neurotransmitters. For example, the locus coeruleus is the major source of 
the neurotransmitter norepinephrine in the brain (Foote et al., 1983) and while it contains 
  
2 
receptors for many types of excitatory and inhibitory neurotransmitters (Ivanov and Aston-
Jones, 1995; Ivanov and Aston-Jones, 2001), it releases only norepinephrine, and the 
regions that receive input from the locus coeruleus contain norepinephrine receptors 
(Aston-Jones et a.l, 2004). 
 
Neurotransmitters bind the extracellular domain of transmembrane receptor proteins, 
resulting in the flow of ions, mostly sodium ions (Na
+
) and potassium ions (K
+
),  across the 
neuronal membrane (Hodgkin and Huxley, 1952; Hille and Catterall, 2006). Binding of the 
receptor causes, either directly or indirectly, the opening of ion channels and the flux of 
ions into the neuron. This helps to establish ion gradients across the neuronal membrane. 
Additionally, other channels contribute to this gradient; sodium:potassium ATPase pumps, 
for example, consume one molecule of adenosine triphosphate (for energy) to move two 
Na
+ 
out of the cell and three K
+
 into the neuron (Albers and Siegel, 2006). This inward and 
outward flow of ions establishes both an electrochemical and concentration gradient, with 
Na
+
 being concentrated outside of the neuron and K
+
 inside. The amount of positive charge 
(Na
+
) outside the neuron is in excess of the amount of positive charge (K
+
) inside, resulting 
in a more positive outside; this is called hyperpolarization, basically defined as a “very 
uneven distribution”. This uneven distribution of atoms and charge sets the stage for action 
potential initiation. 
 
Increased neurotransmitter binding results in increased ion flux and the accumulation of 
Na
+ 
inside the neuron. When excess Na
+
 accumulates in the neuron and the membrane 
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polarization is reduced, that is the hyperpolarization is depolarized, resulting in a more 
even distribution of ions across the membrane, threshold may be reached. Threshold is the 
point where enough Na
+
 has accumulated to activate membrane bound, voltage gated Na
+
 
channel proteins located at the axon hillock, the transitional region between the neuron cell 
body and the axon. Intracellular charged amino acids on the channel protein function as 
voltage sensors and, when a sufficient change in intracellular charge is detected 
(threshold), cause a conformational change in the protein that results in the opening of the 
channel. The voltage-gated Na
+ 
channel is highly specific for Na
+
 and since the 
concentration of Na
+
 outside is much greater than the concentration inside, the opening of 
the channel allows Na
+
 to enter the neuron, resulting in the spread of the depolarization. 
This depolarization spreads to adjacent regions of the axon (upstream Na
+
 channels are 
temporarily inactive), depolarizing them and induces the opening of voltage gated Na
+
 
channels, and ultimately resulting in the release of neurotransmitter. This spreading 
depolarization is the action potential (summarized by Hille and Catterall, 2006).  
 
The speed of action potential propagation can be increased in two ways: (1) extremely 
large caliber axons such as the squid giant axon, which is up to 1 millimeter in diameter, or 
(2) myelinated neurons (reviewed by Hartline and Colman, 2007). Since size and energy 
are limiting factors in life, millions of giant axons in one organism has never been 
observed. Comparisons between a 500 µm unmyelinated squid giant axon and a 12 µm 
myelinated frog axon show that the unmyelinated axon consumes 5,000 times as much 
energy and requires 1,500 as much space to conduct at the same speed (Quarles et al., 
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2006). The savings in space and energy provided by myelin offer an immeasurable 
evolutionary advantage to an organism, allowing for more fast conducting axons in less 
space.  
 
Oligodendrocytes and myelin 
Insulation by myelin, made by oligodendrocytes in the CNS and Schwann cells in the 
peripheral nervous system (PNS), prevents the spreading depolarization, termed current, 
from leaking out of the axon. Myelin is a specialized cell membrane rich in lipids, low in 
cytoplasm, and typically wrapped around itself numerous times. These wraps increase the 
distance between the axon’s intracellular and extracellular environments. This increased 
distance decreases the capacitance of the axon’s membrane by keeping ions sufficiently 
separated so that they are no longer attracted to or repelled by each other, allowing them to 
flow freely upon ion channel activation.  
 
While most cell membranes are half lipid and half protein, myelin is composed of 70-85% 
lipid and 15-30% protein (Gent et al., 1971; Rosetti et al., 2008) with spinal cord having a 
higher ratio of lipid:protein than brain (Quarles et al., 2006). The majority of the protein 
content of myelin is comprised of unique proteins, aiding in the specialized function of 
myelin as an insulator. Proteolipid proteins (PLPs), for example, comprise ~50% of myelin 
protein and behave experimentally as lipids due to numerous lipid modifications (Greer et 
al., 2002). Four isoforms of myelin basic protein (MBPs) comprise ~30% of myelin 
protein and are unique due to multiple states of phosphorylation and methylation (Quarles 
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et al., 2006). 2’3’-cyclic nucleotide 3’-phosphodiesterases (CNPs) (Trapp et al., 1988) and 
myelin-associated glycoproteins (MAGs) (Trapp et al., 1989) are more minor components 
of myelin, with each expressed as two alternatively spliced isoforms and often utilized as 
markers for oligodendrocytes and myelin. 
 
The lipid rich composition of myelin aids in preventing the flow of ions by nature of the 
lipid bilayer. Lipids can form bilayers as a result of interactions between polar (charged) 
head groups of adjacent lipids interacting with one another and with water. Also, the non 
polar (uncharged) tails of lipids are attracted to one another and repel water, facilitating the 
tail to tail alignment of lipids. These polar and nonpolar interactions enable lipids to pack 
tightly together, side by side, resulting in bilayer formation. This bilayer structure, as well 
as interactions with charged proteins (Hu et al., 2004), results in the neutralization of many 
of the remaining charges in the lipids. Together, the separation of these polar and non polar 
regions causes the bilayer to have an overall charge of zero. Ions are not attracted to 
regions of zero charge and will not diffuse through these regions, making lipid bilayers 
quintessential ion flow barriers and myelin, which is up to 85% lipid, is the highest lipid 
content membrane known (Nussbaum et al., 1963). By preventing the flow of ions through 
its own membrane (myelin), the oligodendrocyte increases the resistance of the axon’s 
membrane. Also, myelin is multilamellar, wrapping around the axon numerous times, 
increasing its effectiveness at decreasing capacitance, increasing resistance, and creating an 
even larger region of zero charge.  
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Myelin in the CNS of vertebrates is a distal extension of the cell membrane of 
oligodendrocytes (translates from Greek as “cells with a few branches”) (Figure 1A). 
Oligodendrocytes can exhibit 40 or more branches (Quarles et al. 2006), few compared to 
the hundreds of branches seen in the dendritic arbors of many types of neurons. Each 
branch makes contact with an axon, wraps around it many times (Figure 1B), forming a 
myelin segment. Adjacent myelin segments are separated from each other by nodes of 
Ranvier (reviewed by Rasband, 2006). The node of Ranvier, commonly referred to as the 
node, is a specialized axon domain that lacks myelin and contains a high concentration of 
the voltage gated Na
+
 channels responsible for the propagation of action potentials (Chiu, 
1980; Waxman and Ritchie 1985; Chiu and Schwarz, 1987). Myelination facilitates the 
clustering of Na
+
 channels at the node so that a single, local depolarizing event can open 
vast numbers of channels and cause widespread changes in Na
+
 concentrations. This 
concentration change spreads through the long, myelinated region of the axon, due to 
diffusion and charge repulsion, and activates voltage gated Na
+ 
channels located further 
along the axon. Without the clustering of Na
+ 
channels and insulation created by the 
myelin sheath, electrical signals are transmitted much slower (Quarles et al., 2006) since 
relatively few channels are activated by a single depolarization and only a small region of 
the axon is depolarized.  
 
The result of myelination (myelin structure) has been studied for over 50 years (Fernandez-
Moran et al., 1950; reviewed by Simons and Trotter, 2007). Many of the characteristics of 
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Figure 1. Oligodendrocytes are the myelinating cells of the mammalian central 
nervous system. (A.) An electron micrograph from the laboratory of Dr. Jeff Dupree 
shows an oligodendrocyte extending process and myelinating several axons in a mouse 
spinal cord. This oligodendrocyte appears to have myelinated at least seven axons. 
Numerous small, unmyelinated axons are also shown. (B.) An electron micrograph of a 
myelinated axon in the rat, adapted from Hiran and Dembitzer, 1967. The individual wraps 
are myelin are clear at 166,000x and the first (inner) and last (outer) wraps are labeled.  
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myelin have been thoroughly evaluated in development, disease, and mutant mice 
(Rosenbluth, 1966; Watanabe et al., 1969; Watanabe and Bingle, 1972; Rosenbluth 1976; 
Kirschner et al., 1989; Flores et al., 2008) and are beyond the scope of this thesis. Less 
characterized, but of interest in the last several years are the structural and molecular 
domains that negotiate the interactions between the myelin sheath and the axon, including, 
on each side of the node, the paranode, juxtaparanode, and internode  (Figure 2A, 2B) 
(reviewed by Poliak and Peles, 2003). The internode comprises the majority of the length 
of a myelin segment. In this region the axon and myelin are separated by 12 nanometers 
(nm) (Peters et al., 1976) with myelin:axon adhesion suggested to be mediated by 
unknown mechanisms involving myelin-associated glycoprotein and myelin galactolipids 
(Trapp et al., 1989; Marcus et al., 2002). Internodal myelin is almost completely devoid of 
cytoplasm, and is therefore called compact myelin. Just nodal to the internode is the 
juxtaparanode (reviewed by Rasband, 2004). This region lies along the axon and contains 
concentrations of voltage gated K
+
 channels, believed to play a role in re-establishing 
hyperpolarization following the depolarization that defines action potential propagation. 
Caspr2 and transient axonal glycoprotein-1, also concentrated at the juxtaparanode, are 
believed to aid in the stabilization of K
+ 
channels (Traka et al., 2002; Poliak et al., 2003; 
Traka et al., 2003). 
 
Regarding the paranode, electron microscopic (EM) analyses suggest that each wrap of 
myelin is slightly wider than the previous wrap, resulting in successive points of contact 
between the myelin and the axon (Hirano, 1969). This region of contact is named the 
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paranode and refers to the regions of myelin and axon on each side of the node. The myelin 
at the paranode appears as a series of loops when viewed in longitudinal section and are 
called paranodal or lateral loops. These loops maintain their cytoplasm, giving rise to the 
name uncompacted myelin. Paranodal loops appear as adjacent rain drop-shaped bulges 
with one side touching the previous loop, one side touching the subsequent loop, and the 
bottom “touching” the axon (Figure 2A, 2C). Upon close examination, there is a space of 
2-4 nm between the tip of the paranodal loop and the axon such that these two structures 
are not actually touching (Livingston et al., 1973; Dermietzel, 1974). Spanning the gap 
between the two membranes are structures named transverse bands (Hirano and Dembitzer, 
1967) which, in longitudinal EM sections of myelinated axons, appear as small dark 
slivers. Freeze fracture analysis combined with heavy metal penetration studies revealed 
that these “bands” form a tube-like structure that completely surrounds the axon (Hirano 
and Llena, 1995). Transverse bands are believed to play a major role in holding the myelin 
sheath and the axon together, but their function(s) remain unclear (Rosenbluth et al., 
2003). Freeze fracture work has shown that while the node and juxtaparanode are molecule 
rich, presumably corresponding to the Na
+
 and K
+
 channel proteins, the paranode is 
relatively molecule poor (Rosenbluth, 1976; Rosenbluth, 1981). Three proteins that cluster 
at high density in the paranode are neuronal contactin, contactin’s trafficking partner 
contactin-associated protein (Caspr), and oligodendrocytic neurofascin 155 (Einheber et 
al., 1997; Dupree et al., 1999; Rios et al., 2000; Tait et al., 2000). 
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Figure 2. Nodes, paranodes, and juxtaparanodes are structurally and molecularly 
distinct domains. (A.) An electron micrograph adapted from Marcus et al., 2006 showing 
the structure of a (rat) CNS myelinated axon in longitudinal section. The node is delineated 
by arrows and shown in blue, the paranodes in green, and the juxtaparanodes are in red. 
(B.) An immunolabeled section from a mouse spinal cord demonstrates that sodium 
channels (Nav1.6, blue), Caspr (green), and potassium channels (Kv1.1, red) are specific to 
the node, paranode, and juxtaparanode, respectively.  Adapted from Zonta et al., 2008. (C.) 
An electron micrograph from Hirano and Dembitzer, 1967 shows transverse bands as dark 
slivers between the lateral loops of myelin and the axon. The arrow denotes a single 
transverse band. 
 
 
 
 
 
 
 
  
12 
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Myelin lipids and sulfatide 
The human CNS is over one half lipid (dry weight) (Taylor et al., 2004) due to the higher 
than average lipid content of myelin. Myelin contains concentrations of lipids that are rare 
in other tissues; galactocerebroside, for example, comprises over 20% of myelin lipid 
(Coetzee et al., 1996a) and over 15% of the total content of myelin but is known to be in 
only two other tissues, kidney (Costantino-Ceccarini and Morell, 1973; Stahl et al., 1994) 
and colon (Yahi et al., 1992), and perhaps pancreas (Buschard et al., 1994). The brain 
contains over 20% of the cholesterol present in the human body and the vast majority of 
this is in myelin (Dietschy and Turley, 2004). These concentrations of unique and common 
lipids give the CNS, and more specifically myelin, special properties and provide 
researchers an interesting environment in which to study the roles of lipids in life. Lipids 
are used by organisms to store energy in the form of triglycerides, but these types of lipids 
are nearly absent from the brain (Taylor et al. 2004; Gielen et al., 2006). Myelin lipids, 
therefore, must serve other roles. Lipids as structural components are well studied due to 
their presence in the plasma membranes of all animal cells (Alberts et al., 2002) and 
numerous investigators have recently shown that lipids can also function as signal 
transducers (reviewed by Hooks and Cummings, 2008 and Pyne et al., 2008) and signaling 
platforms (Zhang et al., 2008). While not its only purpose (Menon et al., 2003; Boggs et 
al., 2008) it seems that the defining function of myelin is as an insulator and its special 
lipid composition certainly contributes to this purpose.  
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Lipids, like proteins, can be modified, including glycosylated (Basu et al., 1971), acylated 
(Lee et al., 2001), phosphorylated (Leevers et al., 1996), sulfated (Handa et al., 1974), 
giving rise to tremendous variation in structure and, presumably, function. Recent efforts 
to tease apart the roles of myelin lipids have used transgenic technology in mice. By 
removing (knocking out) parts of genes that code for enzymes involved in lipid synthesis, 
it is possible to create mouse lines that lack a specific enzyme and therefore a specific lipid 
(or a few lipids). For this purpose, the enzyme uridine diphosphate-galactose:ceramide 
galactosyltransferse (CGT) was of special interest (Stahl et al., 1994; Bosio et al., 1996a; 
Bosio et al., 1996b; Coetzee et al., 1996a) since its products, galactocerebroside and 
subsequently sulfatide, both galactolipids, comprise over 25% of the lipid in myelin 
(Coetzee et al., 1996b). Surprisingly, CGT knockout (KO) mice still make myelin, albeit 
less and unstable (Bosio, et al., 1996c; Coetzee et al., 1996b). Also of interest, these mice 
contain abundant glucocerebroside, a lipid that is barely detectable in the normal CNS and 
suspected of partial functional compensation for the lack of galactocerebroside. 
Conduction velocity is reduced in spinal cord axons of CGT KO mice in a manner 
consistent with reduced resistance and/or increased capacitance of the myelin sheath 
(Coetzee et al., 1996b). Additionally, the node and paranode are unstable in the CNS of 
CGT KO mice and transverse bands do not form (Dupree et al., 1998; Dupree et al., 1999), 
suggesting a role for galactolipids in “axo-oligodendrocytic” interactions. Additionally, 
Coetzee and colleagues (1996b) suggest that galactocerebroside and sulfatide are involved 
in myelin compaction (removal of cytoplasm) and tight wrapping of the lamellae due to the 
extensive myelin splitting observed in the ventral column of the spinal cord exclusively in 
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older (45 day old) CGT KO mice. Adding back the CGT gene to only oligodendrocytes, 
via the promoter of the proteolipid proteins, resulted in complete recovery of the animal 
(Zoller et al., 2005), suggesting that oligodendrocyte-specific deficits, not neuronal 
deficits, were responsible for the myelin disruptions.  
 
The formation of compact myelin in the CGT KO mice was surprising and interesting, but 
did not allow for the functions of galactocerebroside and sulfatide to be distinguished. To 
pick apart the differing functions of these lipids, another mouse line was created. Honke 
and colleagues (Honke et al., 2002) generated a mouse that lacks the enzyme cerebroside 
sulfotransferase (CST), the enzyme responsible for the addition of a sulfate to 
galactocerebroside to create sulfatide. Sulfatide (Figure 3A) comprises 4-7% of CNS 
myelin lipid (O’Brien, 1965; Ishazuka, 1997; Gielen et al., 2006; Quarles et al., 2006). 
These mice contain normal amounts of CGT mRNA and galactocerebroside but no CST 
mRNA or sulfatide (Honke et al., 2002). Morphological analyses showed that the myelin 
in these mice is fairly normal up to 15 days of age, with properly compacted but thin 
sheaths (Marcus et al., 2006). Transverse bands were originally not observed in CST KO 
mice (Honke et al., 2002), but do occasionally form (Marcus et al., 2006). Although 
grossly normal in young mice, sulfatide deficient myelin deteriorates with age, showing 
decreased compaction, increased degenerative sheaths, and nodal and paranodal 
breakdown (Figure 3B). Accompanying these myelin abnormalities, the CST mice also 
lose large caliber axons with age. Additionally, it was shown that paired clusters of an 
oligodendrocyte paranodal protein named neurofascin 155 were lost with age in the 
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Figure 3. Sulfatide null mice exhibit unstable paranodes. (A.) A schematic 
representation of the myelin galactolipid sulfatide in its hydroxylated and non-
hydroxylated forms, adapted from Avanti Polar Lipids, Inc. The ceramide and galactose-
derived components are shown and the sulfate group is circled in red. Mutation of the 
enzyme cerebroside sulfotransferase (CST KO) prevents the addition of sulfate to the 
parent molecule galactocerebroside (ceramide plus galactose). (B.) 7 month old CST KO 
mice and MS patients display everted paranodal loops (arrows and arrow heads), indicating 
altered interactions between axons and oligodendrocytes. Adapted from Marcus et al., 
2006 and Suzuki, 1969. (C.) Nfasc155 labeling of the paranode is altered in the CST KO 
mice at 30 days and 7 months of age. Arrows indicate clusters of labeling, representative of 
a paranode. In the WT these clusters are typically observed as a pair. 30 day old CST KO 
mice exhibit increased distance between pairs and more unpaired clusters (arrow heads) 
while paired clusters are nearly absent from 7 month old CST KO mice. Magnification bar 
= 10 µm. Adapted from Marcus et al., 2006. 
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sulfatide null mice (Figure 3C). These investigators concluded that sulfatide is not essential 
for the establishment of proper myelin or axon structure but is essential for the 
maintenance of these structures.  
 
Neurofascin 155 
Neurofascin 155 (Nfasc155), neurofascin 186 (Nfasc186) and neurofascin 140 (Nfasc140) 
were originally identified by Rathjen and colleagues in 1987 (Rathjen et al., 1987) as 
proteins of approximately 155, 186, and 140 kilo Daltons (kDa) that bound an antibody 
directed against glycoproteins from brain plasma membrane extracts. Nfasc140 is a nearly 
unstudied protein and will not be discussed further in this thesis. Only one protein 
(Nfasc186) was studied in this first publication and from its apparent function in attaching 
neurites (fasciculation) to one another in cultures of chicken embryos, the name 
“neurofascin” arose. Coincidentally, this name is also appropriate for Nfasc155, as it is 
now believed to play a role in the attachment between the myelin and the axons at the 
paranode (Tait et al., 2000). Interestingly, the chicken neurofascin (Nfasc) gene contains 
33 exons and gives rise to at least 50 mRNA transcripts (Hassel et al., 1997) but only three 
proteins are know (Nfasc186, Nfasc155, Nfasc140), indicating extreme alternative splicing 
and, presumably, functional mRNA. Due to alternative exon usage (Hassel et al., 1997) 
and similarities in amino-terminal sequencing results (Davis et al., 1993), it is believed that 
these proteins are the result of alternative splicing of the same pre-mRNA and subsequent 
Southern blots suggest that there is only one Nfasc gene (Collinson et al., 1998). 
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Nfasc proteins are members of the Immunoglobulin (Ig) Superfamily and the L1 subfamily 
of proteins. Additional members of the L1 subfamily include L1, neuroglial cell adhesion 
molecule (NgCAM, chicken homologue of mammalian L1), and NgCAM-related cell 
adhesion molecule (NrCAM), each defined by six Ig-like domains, five fibronectin III-like 
(FN3) domains, a transmembrane domain, and a highly conserved cytoplasmic domain 
(Grumet, 1991; Grumet, 1992; Zhao and Hortsch, 1998; Kenwrick et al., 2000). Structural 
analyses of Nfasc186 and Nfasc155 revealed subtle differences in their amino acid 
sequences (Figure 4A) (Volkmer et al., 1992). The Nfasc gene contains exons encoding 
the following major protein domains: (Amino-terminus) signal sequence, six Ig-like 
domains (C2 class), four FN3 domains, a mucin-like/PAT (proline, alanine, threonine rich) 
domain, a fifth fibronectin III-like domain, a transmembrane domain, and a cytoplasmic 
domain (Carboxy-terminus). An early publication stated that there were four FN3 domains 
(Volkmer et al., 1992), but the same laboratory later discovered that there are two exons 
encoding a fifth FN3 domain located between the mucin-like and transmembrane domain-
encoding exons in both chicken and rat Nfasc (Hassel et al., 1997). This fifth FN3 domain 
has been observed in the gene and in several cDNAs but its presence in Nfasc proteins has 
not been evaluated and it is assumed by some investigators to be absent from Nfasc 
proteins (Tait et al., 2000) while others assume that it is present in Nfasc186 (Koticha et 
al., 2005). The third of these FN3 domains is exclusive to Nfasc155 while only Nfasc186 
contains the mucin-like/PAT domain. Other identifying sequence components that 
differentiate Nfasc155 from Nfasc186 include: N-terminal SIGQNE minor domain 
(Nfasc186 only), 17 amino acid insertion domain between Ig-like domains 2 and 3 
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Figure 4. Nfasc155 is an adhesion protein concentrated at the myelin paranode. (A.) 
A schematic presenting the similarities and differences between oligodendrocytic 
Nfasc155 and neuronal Nfasc186. The ? represents the unevaluated fifth fibronectinIII-like 
domain. Adapted from Davis et al., 1996. (B.) Nfasc155, contactin, and Caspr concentrate 
at the paranode and not the node, juxtaparanode, or internode. Sodium channels (NaCh) 
concentrate at the node and potassium channels (KCh) concentrate at the juxtaparanode. 
Yellow indicates green and red labeling in the same plane. Adapted from Sherman et al., 
2005 and Howell et al., 2006. (C.) Nfasc155 and Caspr localize to the mesaxon, the 
spiraling point of contact between the first wrap of myelin and the axon (arrow). Adapted 
from Tait et al., 2000. 
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(Nfasc155 only), and 15 amino acid insertion domain between Ig-like domain 6 and FN3 
domain 1 (Nfasc186 only) (Davis et al., 1996). Interestingly, it is known that the 
Nfasc155-specific third FN3 domain is difficult to make specific antibodies against (Davis 
et al., 1996) and the same observation has been personally communicated by Dr. Manzoor 
Bhat, University of North Carolina. Ig domains are the defining characteristic of antibodies 
due to their role in protein:protein interactions (reviewed by Barclay, 2003) while the FN3 
domains are so named due to their homology to the type III module of the macromolecule-
binding glycoprotein fibronectin (Chernousov et al., 1991; Davis et al., 1993). Similarities 
to Ig and FN3 domains define the L1 subfamily and imply that neurofascin proteins have 
protein binding capabilities. 
 
The mucin-like/PAT domain of Nfasc186 is predicted to be rich in sites of O-linked 
(oxygen-linked) glycosylation (Volkmer et al., 1992) and O-sialoglycoprotease (O-
sialoglycoprotein endopeptidase) degrades Nfasc186 but not Nfasc155 (Davis et al., 1996), 
indicating that Nfasc155 does not contain O-linked glycosylation. Lectin binding studies in 
conjunction with enzymes that specifically remove N-linked (nitrogen-linked) 
glycosylation (peptide:N-glycosidase F (PNGase F) and endoglycosidase H have been 
used to determine that both proteins contain N-linked carbohydrates, but that not all 
predicted sites are glycosylated (Davis et al., 1996). The transmembrane domain of 
Nfasc186 can be palmitoylated in vitro (Ren and Bennett, 1998), suggesting membrane 
microdomain (lipid raft) incorporation in vivo, and while the transmembrane domains of 
Nfasc186 and Nfasc155 are 100% conserved, palmitoylation of Nfasc155 has not been 
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evaluated. The membrane microdomain incorporation of Nfasc155 has been tested, 
however, and it is considered to be a lipid-raft protein by the definitions set forth by the 
authors (Schafer et al., 2004). 
 
The proposed function of Nfasc155 as an adhesion molecule negotiating the attachment of 
the myelin sheath to the axon is strengthened not only by its make up of protein binding 
domains but also by its apparent colocalization (Tait et al., 2000) with contactin (Ranscht 
et al., 1984) and contactin-associated protein {Caspr (Peles et al., 1997), also known as 
paranodin (Menegoz et al., 1997) and ncp1 (neurexin IV, Caspr, paranodin 1, Bhat et al., 
2001)}, both of which are also concentrated at the neuronal paranode, (Einheber et al., 
1997; Rios et al., 2000) (Figure 4B). While the exact details of their interaction is still 
debated (Bonnon et al., 2003; Gollan et al., 2003), it seems that contactin and Caspr 
associate in the endoplasmic reticulum of the neurons and that contactin is required for the 
proper trafficking of Caspr to the paranode (Peles et al., 1997; Bonnon et al., 2003). N-
linked glycosylation states of contactin play a role in binding to Caspr as well as in its 
localization to the paranode (Bonnon et al., 2003; Gollan et al., 2003) and contactin exists 
as two glycoforms (high and low molecular weight contactin) in rat brain, one sensitive 
and one resistant to endoglycosidase H while both are sensitive to PNGase F, indicating 
differing complexities of carbohydrates for each glycoform. Once localized, contactin, also 
a member of the Ig Superfamily, is held in the membrane by glycosylphosphatidylinositol 
linkage and perhaps through its binding with Caspr (anchored via a transmembrane 
domain, Poliak and Peles, 2003). Contactin has been shown to bind Nfasc155 both with 
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(Charles et al., 2002) and without (Gollan et al., 2003) Caspr. Due to the concentration of 
these proteins at the paranode and mesaxon (the spiraling point of contact between the 
myelin sheath and the axon, Figure 4C), their abilities to interact, and the overall lack of 
particles in this region, this trimolecular complex is believed to be a major component of 
transverse bands. Additionally, mice deficient in either contactin (Boyle et al., 2001), 
Caspr (Bhat et al., 2001) or the gene for neurofascin (missing all neurofascin proteins, 
Sherman et al., 2005; Zonta et al., 2008), lack transverse bands. Recently, Nfasc186 was 
reintroduced into the neurofascin KO mouse, creating a Nfasc155 KO mouse (Zonta et al., 
2008). In this mouse, contactin and Caspr do not localize to the paranode while the nodal 
architecture is molecularly restored. 
 
Multiple sclerosis 
Multiple sclerosis (MS), the most common demyelinating disease of the human CNS, is 
defined by focal loss of myelin, termed plaques (reviewed by Trapp et al., 1999). One of 
the goals of MS research is to understand the initial events that take place in the disease, 
thus suggesting a cause. Plaques occur in myelin-rich (white matter) regions of the CNS 
and are often studied to obtain information regarding whether the myelin or the 
oligodendrocyte received the initial insult and how damage occurred (Black et al., 2007; 
Han et al., 2008). In addition, the regions near plaques, normal appearing white matter 
(NAWM) and peri-plaque white matter (PPWM), are also studied since these regions have 
existed in the same environment as the now afflicted area, but lack gross demyelination 
(Zeis et al., 2008). Recently, subtle paranodal abnormalities have been observed in PPWM 
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as well as at the plaque edge and center, including elongation of the paranode (visualized 
with anti-Nfasc155 and anti-Caspr) and abnormal localizations of juxtaparanodal K
+
 
channels and Nfasc155, in the presence of a molecularly normal node (Wolswijk and 
Balesar, 2003; Howell et al., 2006). These paranode-specific alterations are consistent with 
disruptions at the paranode preceding demyelination and axonal pathology in MS. 
 
Questions remain regarding the formation and stability of the paranode 
Three transmembrane proteins located at the paranode, contactin, Caspr, and Nfasc155, are 
able to bind to each other in ways that are still unclear and controversial. Results are 
inconclusive as to whether the high or low molecular weight glycoform of contactin is 
responsible for the binding of Nfasc155  while Caspr has been shown to aid (Charles et al., 
2002; Bonnon et al., 2003) and inhibit (Gollan et al., 2003) contactin:Nfasc155 binding. 
Absence of Nfasc155 results in the absence of contactin and Caspr from the paranode 
(Sherman et al., 2005; Zonta et al., 2008), while Nfasc155 has been shown to aid in 
orchestrating proper molecular arrangement of the node (Zonta et al., 2008), suggesting 
that Nfasc155 plays a major role in the assembly of both the node and paranode. The 
absence of myelin galactolipids in the CGT (Bosio et al., 1996; Coetzee et al., 1996) and 
CST KO (Honke et al., 2002; Marcus et al., 2006) mice, for unknown reasons, show 
paranodal phenotypes similar to contactin, Caspr, and Nfasc KO mice. The results 
presented in this thesis suggest answers to some of these questions. 
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{CHAPTER 2 Materials and Methods} 
 
Mice 
Mice heterozygous for the cerebroside sulfotransferase (CST) gene were obtained from Dr. 
Koichi Honke (Honke et al., 2002). Breeding of these mice results in Mendelian 
distributions of wild type (WT, +/+), heterozygote (+/-), and CST knockout (CST KO, -/-) 
individuals. CST Forward, Long and CST Reverse, Long primers were utilized for 
genotyping the CST mice: (CSTFL: 5’-CTA TTG GAC AAC TAC CCA CTA CCA CCT 
GC-3’ and CSTRL: 5’-GCA CTT ATG TCC GTG TGA GAG TGT CAG GTC-3’). The 
neo cassette (only present in the mutated CST gene) was amplified with the primers CST 
Neo cassette forward and CST Neo cassette reverse: (CSTNEOF: 5’-CAT TCG ACC ACC 
AAG CGA AAC ATC G-3’ and CSTNEOR: 5’-GCA CGA GGA AGC GGT CAG CCC 
AAT-3’).  PCR cycles were as follows: 95°C for 5 minutes, [95°C for 10 seconds, 60°C 
for 10 seconds, 68°C for 20 seconds] for a total of 30 cycles with Sigma-Aldrich’s Klentaq 
DV Ready Mix (St. Louis, MO). WT mice yield only one band at 548 bases, KO mice 
yield one band at 332 bases, and heterozygous mice yield both sizes. Mice were bred and 
maintained in an AAALAC certified facility and all protocols were approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University.  
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Mice mutated at the contactin-associated protein (Caspr) locus were obtained from Dr. 
Manzoor Bhat at the University of North Carolina (Bhat et al., 2001). Survival beyond post 
natal day 21 is rare; accordingly, tissue was harvested at the oldest age available (day 19).  
 
Protein preparation 
Mice were deeply anestatized with 2.5% 2,2,2 tribromoethanol (known as Avertin, Sigma-
Aldrich) in 0.9% NaCl at 0.016 milli Liter (mL) per gram of body mass and decapitated. 
Whole brains and spinal cords were rapidly removed, placed separately in a 
microcentrifuge tube, placed in liquid nitrogen then -80°C for long term storage. Samples 
were drill homogenized on ice in either phosphate buffered saline (PBS: 137 millimolar 
(mM) NaCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.7 mM KCl, pH 7.4) or 
radioimmunoprecipitation assay buffer (RIPA: PBS with 0.1% sodium dodecyl sulfate 
(Fisher, Thermo-Fisher, Pittsburgh, PA), 0.5% sodium deoxycholate (Sigma-Aldrich), 
0.1% nonidet P-40 (Pierce, Thermo-Fisher, Rockford, IL) containing protease inhibitor 
cocktail (Sigma-Aldrich) for 3 minutes, (2-3 mL, spinal cord) or 5 minutes (5 mL, brain) at 
4000 revolutions per minute (rpm). Homogenates were centrifuged in a microcentrifuge for 
one minute at 13,000 revolutions per minute to remove remaining pieces of tissue and 
insoluble material. The supernatant was removed to a new tube; a 50 µL sample was set 
aside for protein assay, and stocks were stored at -20°C until protein assay was completed. 
Protein concentrations were determined with the Micro BCA Protein Assay Kit by Pierce 
according to the manufacturer’s protocol. Dilutions of bovine serum albumin were used to 
create the standard curve. Four dilutions per sample, triplicate of each, were made and 
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compared to the standard curve (absorbance at 562 nanometers) using the Spectra Max 
Plus spectrophotometer (Molecular Devices, Sunnyvale, CA). Protein concentrations were 
determined for each dilution, averaged, and one half of each sample was diluted to two µg 
per µL with RIPA. To this, one volume of final sample buffer (Laemmli, 1970), now 
known as Laemmli sample buffer (Bio-Rad, Hercules, CA: 62.5 millimolar Tris-HCl, pH 
6.8, 2% sodium dodecyl sulfate, 25% glycerol, 0.01% Bromophenol Blue), containing 5% 
freshly added β-mercaptoethanol (Sigma-Aldrich) was added and samples were aliquoted 
at 100 µL per tube and stored at -80°C. Prior to loading onto a gel, protein samples were 
incubated in a 100°C heat block for 5 minutes, briefly centrifuged to collect all fluid, 
mixed with a pipet tip and added to the gel.  
 
Western blotting 
For gel electrophoresis, 20-25 µg of spinal cord proteins and 40-50 µg of brain proteins 
were run on 10% Ready Gels (Bio-Rad) containing 10 wells with a maximum volume of 
50 µL per well. Gels were run in electrode buffer (192 mM glycine, 25 mM Tris, 0.1% 
sodium dodecyl sulfate) with Bio-Rad’s Mini Protean 3 cell and power was supplied by 
Bio-Rad’s Power Pac HC. For repeatable separation of neurofascin 155 high and 
neurofascin 155 low, the gels were run until the 75 kDa band of the Kaleidoscope ladder 
(Bio-Rad) was at the bottom of the gel (approximately 30 minutes at 70 volts then 2 hours 
at 150 volts). Upon completion of the run, gels were carefully removed from their holding 
apparatus and misshapen edges were removed while the lanes and stacking gel were cut off 
the top.  
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The gel was soaked in transfer buffer (192 mM glycine, 25 mM Tris with 20% methanol, 
stored at -20°C while the gel was running) for 10-20 minutes. The gel was prepared for 
transfer as follows: negative (black) side of the clamp down, absorbent mesh, Mini Trans 
Blot Filter Paper, gel (left front of the gel facing down and right), 0.45 µm pore size 
nitrocellulose (roll out bubbles), Mini Trans Blot Filter Paper (roll out bubbles), absorbent 
mesh. The clamp was carefully shut and placed in the transfer apparatus along with a small 
stir bar. The apparatus was placed in an ice-water bath approximately five times the 
volume of the apparatus and the bath plus apparatus was placed on a magnetic stirrer set to 
low spin throughout the transfer. The proteins were transferred for two hours at 100 volts, 
with an internal ice change after one hour. Upon completion of the transfer, the sandwich 
was disassembled and the membrane immediately placed in excess PBS and placed on a 
rotator. PBS was changed every ten minutes for a total of three changes and the membrane 
was blocked in 5% non-fat dry milk (Bio-Rad) in PBS containing 0.05% Tween-20 
(Sigma-Aldrich) for 45 minutes. Primary antibodies were incubated at 4°C overnight on a 
rotator; FIGQY at 1:2,000, NFC1 at 1:40,000. ERK2 dilutions varied depending on the 
amount and origin of the protein loaded; 1:1000 for under 10 µg, 1:5,000 for 10-20 µg, and 
1:10,000 for over 20 µg of spinal cord protein and 1:50,000 for 40 µg of brain protein. The 
following day, the antibody was removed and the membrane was rinsed several times in 
PBS until milk was no longer visible. The membrane was incubated in PBS with changes 
every ten minutes for a total of three changes then blocked a second time for 30 minutes in 
5% milk PBS containing 0.05% Tween-20. Secondary antibodies conjugated to horse 
radish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA) were diluted 1:10,000 
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(added to the block) and incubated with the membrane for two hours at room temperature 
(20-25°C). Following the removal of the secondary antibody, PBS was added and changed 
until milk was no longer visible, and PBS containing 0.05% Tween-20 added for 10 
minutes with one change. Finally, the membrane was rinsed three times with PBS, ten 
minutes each time. SuperSignal West Dura Extended Duration Substrate (Pierce) allowed 
for visualization of the locations of the proteins of interest. Imaging and image analysis 
performed with the AlphaInnotech Fluorchem SP device and AlphaInnotech AlphaEase 
software (San Leandro, California). 
 
Immunohistochemistry 
A 7 day old rat pup was anesthetized with avertin (2,2,2, tribromoethanol, 2.5% (w/v) in 
0.9% sodium chloride) and transcardially perfused with 4% paraformaldehyde (pH 7.3). 
The spinal cord and brain were immediately harvested, cryopreserved in 30% sucrose in 
PBS, frozen in Optimal Cutting Temperature compound (Sakurak, Torrance, CA), and 
sectioned at 10 µm. Sections were double immunolabeled with antibodies directed again 
neurofascin proteins (named FIGQY) and Caspr. Briefly, sections were incubated in -20°C 
acetone for 10 minutes, blocked in PBS containing 10% cold water fish gelatin and 0.1% 
Triton X-100. Primary antibodies were diluted in the blocking buffer at 1:200 (FIGQY) 
and 1:1000 (anti-Caspr), incubated overnight at 4°C, and sections were washed in PBS and 
blocked a second time. Appropriate fluorescent labeled secondary antibodies were 
incubated with the sections for 90 minutes and visualized with a Leica TCS-SP2 AOBS 
laser confocal microscope. Images were collected a maximum projection Z stack images 
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compiled from six optical sections using a 63x oil immersion objective with a numerical 
aperature 1.3. Microscopy was performed at the Virginia Commonwealth University 
Department of Anatomy and Neurobiology Microscopy Facility. 
 
Antibodies, loading control, and molecular mass standards 
The rabbit polyclonal pan-neurofascin antibody known as “FIGQY” is named after the 
amino acid sequence phenylalanine, isoleucine, glycine, glutamine, tyrosine located in the 
C-terminal antigen CSFIGQYTVRK (Ogawa et al., 2006). This antibody was generated in 
the laboratory of Dr. Matthew Rasband, Baylor College of Medicine, and I greatly 
appreciate his generosity in providing the ample amounts of antibody required for this 
project. The FIGQY region was chosen because the tyrosine residue has been previously 
shown to play a role in phosphorylation-state dependent cytoskeletal interactions (Tuvia et 
al., 1997) and Dr. Rasband personally communicated that the FIGQY antibody was 
generated to be phosphorylation-state specific, but it is not. A second rabbit polyclonal 
pan-neurofascin antibody known as “NFC1” and directed against the extreme C-terminus 
sequence CGNESSEATSPVNAAIYSLA was obtained from Dr. Peter Brophy, University 
of Edinburgh (Tait et al., 2000). Both FIGQY and NFC1 are directed against the 
cytoplasmic, C-terminus region of neurofascin proteins but the two antigen sequences do 
not overlap.  
 
To control for loading of the gel and transfer of the proteins from the gel to the 
nitrocellulose, extracellular-signal-related kinase 2 (ERK2) was detected with a rabbit 
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polyclonal IgG antibody (clone C14, Santa Cruz Biotechnology). This protein fits all of the 
parameters for a potential loading control: (1) present during the time point(s) of interest 
(2) unaltered levels during the time point(s)/treatments of interest (3) readily detectable 
with an available antibody (4) molecular mass fits into the project. 
 
The apparent molecular masses of proteins were estimated on the membrane with Magic 
Mark XP Western Standard (MM) (Invitrogen, Carlsbad, California), a standard detected 
by various HRP-conjugated secondary antibodies. Kaleidoscope Ladder (KL) (Bio-Rad) 
allows for monitoring of a gel run and the efficiency of transfer. Eight µL of this ladder is 
completely transferred during a two hour electrophoretic transfer at 100 volts. The red, 75 
kDa band was run to the bottom of the gels to allow for optimal separation of the proteins 
examined. 
 
PNGase F 
Peptide: N-glycosidase F (PNGase F, New England Biolabs, Ipswich, MA) is an enzyme 
that removes N-linked carbohydrates from proteins. The enzyme cleaves between the 
asparagine containing the carbohydrate and the first N-acetylglucosamine, removing the 
entire carbohydrate and leaving an aspartic acid residue in place of the asparagine. For 
establishment of the protocol and deglycosylation for western blot experiments, 20-70 µg 
of protein was denatured in 1x glycoprotein denaturing buffer (10x is 5% sodium dodecyl 
sulfate, 0.4 molar dithiothreitol) at 100°C for ten minutes and deglycosylated by incubating 
with 1x G7 reaction buffer (10x is 0.5 molar sodium phosphate, pH 7.5), 1% nonidet P-40, 
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and 1-3 µL PNGase F at 37°C for one-four hours. For experiments designed to 
deglycosylate abundant immunoprecipitated proteins of interest, approximately 400 µL of 
purified, denatured glycoprotein in 1x glycoprotein denaturing buffer was brought to 700 
µL with 1x G7 reaction buffer, 1% nonidet P-40, water, 5 µL PNGase F and incubated at 
37°C for two hours. One volume of Laemmli sample buffer containing 5% β-
mercaptoethanol was added to stop the reaction and the samples were stored at -20°C. 
 
The NetNGlyc Server 1.0 (http://www.cbs.dtu.dk/services/NetNGlyc/) was used to predict 
locations of N-linked glycosylation (PubMed accession AAL27854, rat Nfasc155 kDa 
isoform) as well as the likelihood that a given site is glycosylated in vivo. Highly likely is 
defined as above 0.5 threshold, 9/9 neural networks agreeing on the outcome, and a + + 
result. Somewhat likely is defined as above 0.5 threshold, 6 or more neural networks 
agreeing on the outcome, and a + result. Only NXS/T (asparagine, any amino acid, serine 
or threonine) sequons free of proline and located in the cytoplasmic region were 
considered. Molecular mass was calculated with the ExPASy Compute pI/MW tool 
available at www.expasy.ch/tools/pi_tool.html. 
 
Human tissue 
Brain and spinal cord tissues were obtained upon request from Rocky Mountain Multiple 
Sclerosis Center (www.mscenter.org; Englewood, CO). Three main categories of brain 
tissues were received: non multiple sclerosis (MS), normal appearing white matter 
(NAWM) from MS patients, and MS patient tissue. For spinal cords, only MS patient 
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tissue was available. Four of each, non MS and NAWM, eight MS brain samples, and six 
spinal cord samples were received. Samples were approximately six by three centimeters. 
One-third of each sample was cut off, homogenized in one mL RIPA buffer and processed 
for western blot as stated above.  
 
Immunoprecipitation 
In an attempt to identify the proteins of interest with mass spectrometry, optimal 
conditions for the immunoprecipitation (IP) of neurofascin 155 high and neurofascin 155 
low were determined empirically as follows. Mouse spinal cord homogenates in RIPA 
alone showed very little protein of interest following IP with the FIGQY antibody. 
Pretreatment of the homogenates with 1% Triton X-100 (ICN Biomedicals, Inc., Aurora, 
OH) resulted in a dramatic increase in the amount of protein recovered; perhaps due to the 
disruption of lipid spheres containing neurofascin proteins (via its hydrophobic, 
transmembrane domain) where the cytoplasmic antigen sequence would be inaccessible to 
the antibody/antibodies. All centrifugation steps in the IP are 5,000 rpm for one minute, 
however, since the pellet is the point of interest, all homogenates were pre-centrifuged for 
five minutes at 13,000 rpm the day that they were homogenized and one minute at 8,000 
rpm the day of the IP to remove insoluble material. To remove endogenous antibodies and 
other naturally adhesive molecules, homogenates were treated with Protein A/Protein G 
agarose plus (PAGA, Santa Cruz Biotechnologies) for two hours in a 4°C cold room on an 
inverting rotator. Samples were centrifuged, the pellet discarded, and the supernatant 
incubated with FIGQY primary antibody. Incubations and volumes varied depending on 
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whether the purpose was to work out the basic protocol or to capture enough protein for 
downstream use. To work out the basic protocol, 500 µg of spinal cord protein and 10 µL 
of FIGQY primary antibody yielded enough protein of interest to be visualized by western 
blot. To attempt to identify proteins by mass spectrometry and consume a minimum of 
antibody, serial IP was conceived. Serial IP is the repeated IP of one supernatant to 
evaluate the volume of antibody required to remove all target protein from the supernatant. 
It was found that approximately 100 µL of FIGQY can remove virtually 100% of the 
proteins of interest from one adult rat spinal cord homogenate (roughly 45 mg of protein). 
Since this method worked with “only” 100 µL of FIGQY and other methods consumed 
more yet yielded less than 100% target, the serial IP method was utilized further. One half 
of one adult rat spinal cord homogenate was incubated with 200 µL PAGA for two hours 
(all steps are at 4°C on an inverting rotator), centrifuged to remove the PAGA and any 
endogenous matter that it bound, and the supernatant was incubated with 50 µL of FIGQY 
for 2-4 hours then 100 µL of PAGA overnight. The following day, the IP was centrifuged, 
the pellet washed twice with cold RIPA and stored on ice while the supernatant was 
incubated with 20 µL of FIGQY for two hours followed by 50 µL of PAGA for two hours. 
This step was repeated, consuming 90 µL of FIGQY total and yielding a pellet of PAGA 
and target of approximately 100 µL. The second half of the rat spinal cord was then treated 
with Triton X-100 and 200 µL of PAGA and incubated overnight with the PAGA:target 
pellet and another 10 µL of FIGQY. The following day, the pellet was washed four times 
with cold RIPA and proteins eluted in 300 µL 1x glycoprotein denaturing buffer (from the 
PNGase F protocol) at 100°C for ten minutes, centrifuged, supernatant harvested, and 
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another 100 µL 1x glycoprotein denaturing buffer added to the pellet, heated, centrifuged, 
harvested. Eluted proteins (~450 µL) were treated with 5 µL of PNGase F (see PNGase F, 
Materials and Methods). Deglycosylated samples were centrifuged in centricon-30 
columns (Centricon, now Millipore, Billerica, MA) for one to two hours at 6,000 rpm at 
4°C to reduce the volume sufficiently for gel electrophoresis. The centrifugation was 
monitored periodically and stopped when the fluid reached 40 µL. Following the protocol 
provided with the columns, the tubes were inverted, placed in a collection vial, and 
centrifuged at 2,000 rpm for five minutes to collect the protein concentrate. Laemmli 
sample buffer was added (40µL) and 50 µL was loaded on a gel. 
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{CHAPTER 3 Results} 
 
Neurofascin 155 is reduced in sulfatide null mice 
In 2006, this laboratory published that Nfasc155 clusters in the paranode of sulfatide null 
mice but, unlike WT littermates, these clusters deteriorate with age, resulting in nearly 
complete loss of paranodal clusters by 7 months of age (Marcus et al., 2006). The current 
project began as an inquiry into whether this dramatic loss of paranodal clustering of 
Nfasc155 was due to reduced clustering of Nfasc155 at the paranode or loss of Nfasc155 
altogether. As shown in Figure 5A, spinal cord homogenates from 15 day, 30 day, and 7 
month old CST KO mice contain less Nfasc155 than their respective littermate WT. 
Fifteen day old sulfatide null spinal cords contain 52% less Nfasc155 (standard deviation 
(SD)=33%, p=0.003) than littermate WT (SD=21%). By 30 days of age, Nfasc155 is 24% 
reduced (SD= 14%, p=0.044) in the CST KO compared to WT (SD=16%). While the 7 
month old CST KO mice appear to contain 40-60% less Nfasc155, attempts to quantify 
these results yielded numbers that did not always match what the western blot suggested 
and this will be addressed in the next section. Figure 5B shows that both the 46 and 48 kDa 
isoforms of CNP follow their normal expression profiles and that the abundance of each 
isoform is unaltered by the absence of sulfatide at 15 days, 30 days, and 7 months of age. 
Unpublished work from this laboratory shows that CNPs are expressed normally at birth, 3 
and 7 days of age in the CST KO and that MBPs levels are unaltered at all ages mentioned 
(data not shown). Together, these results suggest that myelin proteins are expressed 
normally and that Nfasc155 is present, albeit at reduced levels, in the absence of sulfatide,  
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Figure 5. Nfasc155 is significantly and specifically reduced in the absence of sulfatide. 
(A.) Western blot analysis of Nfasc155 shows significant decreases at 15 (52%) and 30 
days (24%) of age. While Nfasc155 appears reduced in the 7 month old CST KO, this was 
not significant, believed to be due to observed inconsistencies between the WT and CST 
KO. Evaluation of these inconsistencies led to the results shown in Figure 5. Nfasc140 is 
visible just below Nfasc155 in the 7 month old WT. (B.) CNP 48 (CNP high) levels are not 
altered in the absence of sulfatide and the CNP 46 (CNP low) expression profile is also 
normal. Additionally, MBP levels are normal in the CST KO mice at these same ages 
(unpublished observations from this laboratory), demonstrating a specific reduction in 
Nfasc155 in the absence of sulfatide. 
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indicating that the near complete loss of paranodal clusters at 7 months of age is due to 
reduced clustering, not a loss of the protein itself.  
 
The neurofascin 155 band seen on western blots contains two bands, one of which is 
altered in the absence of sulfatide 
The process of optimizing the separation of Nfasc186 and Nfasc155 showed irregular 
results, especially in animals 3 months of age and older. Most notably, there appeared to be 
a shift in the location of Nfasc155, without a comparable shift in Nfasc 186, in the CST 
KO, leading to experiments designed to address this issue. Further optimization resulted in 
gel runs in excess of two hours and it was realized that WT mice three months of age and 
older contain two bands/proteins (hereafter referred to as proteins) where only a single 
Nfasc155 band is expected (between Nfasc186 and Nfasc140) while CST KO mice contain 
only one. These two proteins are now named “neurofascin 155 high” (Nfasc155H) and 
“neurofascin 155 low” (Nfasc155L) due to their previous inclusion in a single band. 
 
The western blots shown in Figure 6A (FIGQY primary antibody, which is the antibody 
used in all subsequent figures, unless otherwise noted) and 6B (NFC1 primary antibody) 
show only Nfasc155H (with a slight shadow below it) at 15 days of age in both WT and 
CST KO, with the KO appearing reduced. At 30 days of age, the WT presents Nfasc155H 
as an intense band with an obvious shadow below while the CST KO shows both 
Nfasc155H and Nfasc155L with an apparent decrease in the amount of Nfasc155H 
compared to WT. Seven month old WT mice appear to contain nearly equal amounts of  
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Figure 6. Extended electrophoresis reveals two bands where only Nfasc155 is 
expected and only one of these bands appears reduced in the absence of sulfatide. 
Two bands, now called neurofascin 155 high (Nfasc155H) and neurofascin 155 low 
(Nfasc155L) are observed when electrophoresis is conducted beyond the usual one hour 
protocol. In mouse spinal cord (A., B.), the pan-neurofascin antibodies FIGQY (A.) and 
NFC1 (B.) both demonstrate this novel pattern. The WT and CST KO resemble each other 
at 15 days of age, but at 30 days of age the WT presents the intense Nfasc155H band with 
a shadow below while the CST KO shows both Nfasc155H and Nfasc155L at similar 
intensities. At 7 months of age the WT presents Nfasc155H and Nfasc155L while the CST 
KO presents virtually no Nfasc155H and approximately normal amounts of Nfasc155L. 
(C.) Mouse brain homogenates incubated with FIGQY show a similar pattern, except that 
Nfasc155L is clearly present at 30 days of age in the WT.  
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Nfasc155H and Nfasc155L while CST KO mice exhibit almost no Nfasc155H and normal 
(6A) or reduced (6B) amounts of Nfasc155L. Due to extremely limited amounts of the 
NFC1 antibody, it was not possible to address this difference directly; however, work to be 
presented will resolve this difference. Figure 6C shows mouse brain samples incubated 
with FIGQY and a pattern similar to that seen in the spinal cord. The major difference in 
the brain is the clear presence of Nfasc155L in the 30 day WT sample. For the remainder 
of this thesis, “Nfasc155” refers to the protein previously described in the literature and 
maintained as PubMed Accession AAL27854, Nfasc155 kDa isoform, Rattus norvegicus, 
while “Nfasc155H” and “Nfasc155L” refer to the proteins described here for the first time. 
 
Rats resemble mice regarding Nfasc155H and Nfasc155L 
To further understand how Nfasc155H and Nfasc155L change with age, multiple closely 
aged samples were analyzed. Previous observations suggested that rats, like mice, contain 
Nfasc155H and Nfasc155L and rats of the desired ages were harvested to evaluate rat as an 
additional model. As shown in Figure 7A, Nfasc155H increases in intensity from 7 through 
27 days of age, decreases between 27 days and 3 months of age, and is maintained between 
3 and 5 months of age. Nfasc155L is not observed as a distinct band until 3 months of age 
and is also observed at 5 months of age. Also similar to mouse, rat spinal cords exhibit a 
shadow below Nfasc155H at approximately one month of age (30 and 27 days of age in 
mouse and rat, respectively). A thorough examination of the literature revealed brief 
mentions (Volkmer et al., 1992; Maier et al., 2005) and western blot images (Schafer et 
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al., 2004) of a Nfasc155 doublet, with variable glycosylation being suspected as the cause 
(Maier et al., 2005). 
 
PNGase F treatment provides a novel tool to study Nfasc155H and Nfasc155L 
Earlier work on the neurofascin proteins indicated that they are glycosylated and respond 
to treatment with PNGase F, an enzyme that specifically removes N-linked carbohydrates 
from proteins (Volkmer et al., 1992; Davis et al., 1993). Based on the results shown in 
Figures 6 and 7A, it was hypothesized that Nfasc155H and Nfasc155L were the same 
polypeptide with varying amounts of N-linked glycosylation and that treatment with 
PNGase F would result in the collapse of the two bands into one “smaller” band. This 
hypothesis is consistent with previous finding with the two glycoforms of contactin, the 
proposed binding partner of Nfasc155 (Bonnon et al., 2003). Figure 7B shows rat spinal 
cord samples from various ages after treatment with PNGase F. Foremost, Nfasc155H and 
Nfasc155L did not collapse into one band following treatment and each band was not only 
maintained but better separated and therefore more clearly visible. Accordingly, PNGase F 
was utilized in many other parts of this study. This observation suggests that these two 
proteins are unique based on differences other than N-linked glycosylation. Additionally, 
the 7 day old spinal cord contains barely detectable Nfasc155H (Figure 7B) and the level 
increases steadily with age between 7 and 27 days of age, resulting in an approximately 
four fold increase (as determined by densitometry). Between day 27 and 3 months of age 
Nfasc155H levels are reduced by approximately 50% and are then maintained between 3 
and 5 months of age. This profile coincides with myelination (Collinson et al., 1998);  
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Figure 7. Nfasc155H and Nfasc155L are developmentally regulated. Rat spinal cord 
samples are shown from various ages, demonstrating the relative changes in the amount of 
each protein with age. (A.) Extended electrophoresis shows steadily increasing amounts of 
Nfasc155H from 7 to 27 days of age followed by a reduction by 3 months of age. 
Nfasc155L, first visibly distinct at 3 months of age, appears to form from the shadow 
below Nfasc155H at 21 and 27 days of age. (B.) PNGase F treatment of the same samples 
reveals onset of Nfasc155L between 7 and 14 days of age. Nfasc155H reaches peak levels 
at 27 days of age while Nfasc155L continues to increase in abundance up to 5 months of 
age. While Nfasc155H is more abundant from 7 to 27 days of age, Nfasc155L is more 
abundant than Nfasc155H at 3 and 5 months of age.  
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however, levels of major myelin proteins are maintained after myelination peaks (Coetzee 
et al., 1998). Nfasc155L is not detected at 7 days of age, increases steadily with age 
thereafter, and appears more abundant that Nfasc155H at 3 and 5 months of age. Of the 
ages examined, 5 months shows the highest level of Nfasc155L. Interestingly, without 
PNGase F, Nfasc155L is not clearly observed until 3 months of age (Figure 7A) while with 
PNGase F it is observed by 14 days of age (Figure 7B). 
 
Nfasc155H clusters at the paranode 
The observation that Nfasc155H, and not Nfasc155L, is present at 7 days of age provided a 
unique age at which to evaluate the localization of Nfasc155H. Immunohistochemistry of a 
7 day old rat spinal cord double labeled with FIGQY and anti-Caspr antibodies shows 
intense Caspr reactivity at the paranode and FIGQY reactivity at the paranode and node 
(Figure 8). Labeling of the node with FIGQY is consistent with the distribution of 
Nfasc186 (Davis et al., 1996; Schafer et al., 2004) and the paranodal labeling is likely 
Nfasc155H (Tait et al., 2000; Howell et al., 2006).  
 
Nfasc155H is specifically altered in the absence of sulfatide 
To further analyze the differences between WT and CST KO mice of varying ages, as 
observed in Figure 6, PNGase F was employed. Figure 9 presents 15 day, 30 day, and 4 
month old mouse spinal cord homogenates treated with PNGase F and run alongside 
untreated controls. No difference was observed between 3, 4, 7, and 9 month old mice 
regarding Nfasc155H and Nfasc155L patterns. 
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Figure 8. Nfasc155H localizes to and clusters in the paranode. At 7 days of age, when 
Nfasc155H is observed via western blot and Nfasc155L is not yet present, the pan-Nfasc 
antibody FIGQY (green) labels the node (presumably Nfasc186) and the paranode (most 
likely Nfasc155H) in rat spinal cord. Anti-Caspr defines the paranode (red) and node 
(blank region between the red regions). The merged image shows Nfasc155H and Caspr as 
orange, representing the paranode, and Nfasc186 as green, representing the node. 
Magnification bar = 5µm 
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Two important points were made by this experiment. First, Nfasc155H, but not 
Nfasc155L, is specifically reduced in the absence of sulfatide. Second, while it is not 
known with absolute certainty that the band labeled “Nfasc155L” in the PNGase F treated 
15 and 30 day old WT samples is the same protein seen in the 4 month old WT and KO 
(untreated and treated), and seen in Figure 7, a systematic evaluation provides strong 
evidence that they are the same. The 4 month old WT shows three major bands (Nfasc186, 
155H, 155L) with and without PNGase F, while the 4 month old CST KO shows only two 
major bands (Nfasc186, 155L) with and without PNGase F (Figure 9). This indicates the 
locations (on the blot) of Nfasc186, Nfasc155H, and Nfasc155L after treatment with 
PNGase F and allows extrapolation to the younger WT mice, confirming the presence of 
Nfasc155L (as defined by location on the blot at 4 months of age) at 15 and 30 days of age 
and in both WT and CST KO.  
 
The source of Nfasc155L in the 15 and 30 day old animals has been analyzed in two ways. 
Density measurements of the Nfasc186 band in all lanes, untreated and PNGase F treated, 
strongly suggest that Nfasc186 simply shifts following treatment and does not contribute to 
the intensity of any other band. Additionally, density measurements of the robust band 
labeled “Nfasc155H” in the 15 and 30 day old untreated WT samples are less than 10% 
different from the sum of the proposed Nfasc155H and Nfasc155L observed following 
PNGase F treatment. This is consistent with the band labeled “Nfasc155L” in the 15 day 
old WT PNGase F treated lane being derived from within the robust band labeled 
“Nfasc155H” in the 15 day old WT untreated lane. Furthermore, these results suggest that  
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Figure 9. Nfasc155H, but not Nfasc155L, is dramatically reduced in the absence of 
sulfatide. Untreated and PNGase F treated homogenates from mouse spinal cords of 
various ages reveal that Nfasc155H  is reduced in the CST KO mice while Nfasc155L 
levels are comparable to age-matched WT. At 15 and 30 days of age, Nfasc155L (in the 
PNGase F treated lanes) appears to have come from the shadow below Nfasc155H (in the 
untreated lanes). Most interestingly, at 4 months of age the CST KO shows no Nfasc155H 
(arrow). This same result has been observed at 3, 7, and 9 months of age while these mice 
survive to 15 months of age. WT- = WT untreated, WTP = WT PNGase F treated, KO- = 
CST KO untreated, KOP = CST KO PNGase F treated 
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Nfasc155L is somehow masked in untreated younger animal samples, perhaps by the more 
abundant Nfasc155H or perhaps by subtle changes in N-linked glycosylation with age 
causing it to migrate closer to Nfasc155H in younger animals, consistent with Figure 7.  
 
Nfasc155L contains more N-linked glycosylated sites than does Nfasc155H 
Molecular mass comparisons between untreated and PNGase F treated lanes in animals 
over 1 month of age were standardized to an immunoladder revealing a 12 kDa shift for 
Nfasc155H and a 17 kDa shift for Nfasc155L (Figure 9). This 5 kDa difference suggests 
either more sites of N-linked glycosylation or more extensively glycosylated sites for 
Nfasc155L. Additionally, analysis with NetNGlyc 1.0 Server predicts five highly likely 
and two somewhat likely sites of N-linked glycosylation for rat Nfasc155, consistent with 
multiple sites suggested by the western blot-derived data. Analysis of the apparent 
molecular masses of Nfasc155H and Nfasc155L shows that after treatment with PNGase F 
both proteins migrate above 132 kDa, the predicted amino acid mass of Nfasc155, 
indicating the likely presence of other post-translational modifications and demonstrating 
that components other than N-linked glycosylation must account for the difference in the 
apparent molecular masses of Nfasc155H and Nfasc155L. 
 
Nfasc155H, not Nfasc155L, requires detergents for efficient extraction from CNS 
tissue 
Early in the project it was noticed that tissue samples prepared by different researchers 
yielded different results regarding Nfasc155H and Nfasc155L migrations patterns, 
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however the significance of these observations was not readily appreciated. Prior to the 
discovery of the ability of PNGase F to aid in clearer resolution of Nfasc155H and 
Nfasc155L, multiple (untreated) samples were run in an attempt to quantify the two 
proteins for statistical analysis. Figure 10 combines two images designed to analyze 
Nfasc155H and Nfasc155L levels at 15 (Figure 10A) and 30 days of age (Figure 10B). 
Samples at each time point were gathered from another researcher in the laboratory and run 
alongside samples that had already been analyzed. The results did not match previous 
results and it took time to finally realize why. The other researcher’s samples had been 
homogenized in PBS (all samples to this point were homogenized in RIPA buffer) and 
unexpectedly showed clear Nfasc155L in WT and CST KO mice at both 15 and 30 days of 
age. This suggested that Nfasc155L is present in the spinal cord of WT mice at 15 and 30 
days of age but that, for unknown reasons, it was not visible in the RIPA samples. 
Additionally, much of the Nfasc155H appeared to be absent from the PBS homogenized 
samples at both ages. 
 
To answer the question of why PBS and RIPA homogenized samples gave different results 
required a novel experimental approach. To understand this difference, (WT) tissue was 
harvested and specifically homogenized in either PBS or RIPA, treated with PNGase F, 
and the western blot-derived densities of Nfasc155H and Nfasc155L compared. Figure 11 
is derived from one adult rat; its brain was cut in half longitudinally, with one half 
homogenized in RIPA and the other half in PBS. The same procedure was carried out on 
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Figure 10. RIPA and PBS homogenized spinal cords show different patterning of 
Nfasc155H and Nfasc155L at 15 and 30 days of age. Attempts to quantify the 
differences observed between WT and CST KO mice were halted when it was realized that 
RIPA and PBS homogenized samples give different results. (A.) 15 day old WT spinal 
cords homogenized in PBS show less Nfasc155H compared to samples homogenized in 
RIPA and Nfasc155L is unexpectedly visible in the PBS WT samples. RIPA and PBS 
homogenized 15 day old CST KO samples are indistinguishable. (B.) At 30 days of age, 
PBS WT samples exhibit less Nfasc155H than the RIPA WT, while the RIPA WT shows 
intense Nfasc155H with a shadow below. Surprisingly, Nfasc155L is clearly visible in the 
PBS WT lanes. Similar to the 15 day old spinal cords, RIPA and PBS homogenized CST 
KO are indistinguishable at 30 days of age. The unexpected results of less Nfasc155H and 
visible Nfasc155L in PBS homogenized samples at both ages led to further evaluation of 
the differences between RIPA and PBS. 
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the spinal cord. As expected, the detergent-containing RIPA buffer extracts more total 
protein (as per the protein assay) than the detergent-lacking PBS (62% less in the brain and 
64% less in the spinal cord). To account for this reduction in protein and allow for 
comparisons between RIPA and PBS, the densitometry of each RIPA band was reduced by 
the appropriate percentage. Only the PNGase F treated lanes were compared and RIPA 
bands were assigned to 100%. Figure 11 shows that PBS extracts only 4% of Nfasc155H 
from brain (see example calculation below *) and 55% from the spinal cord of an adult rat. 
In contrast, Nfasc155L is more readily extracted without detergents; yielding 100% from 
brain and spinal cord (118% and 174% respectively, indicating that Nfasc155L comprises  
a larger portion of the total protein population in PBS compared to RIPA, similar to ERK2, 
data not shown). These differences demonstrate varying extractabilities of the two proteins, 
with Nfasc155H being less extractable than Nfasc155L, and suggest that different 
intermolecular interactions regulate the variable localization/functions of Nfasc155H and 
Nfasc155L. Additionally, Nfasc155H extracts differently from brain and spinal cord, 
demonstrating varying interactions even within the CNS. These results suggest an 
explanation of why PBS homogenized samples (Figure 10) previously showed Nfasc155L 
at 15 and 30 days of age when RIPA did not (Figures 6, 7, 9); in PBS, much less 
Nfasc155H is extracted while comparable amounts of Nfasc155L are extracted, allowing 
for visualization of the much less prevalent Nfasc155L. Also of interest, between 
Nfasc155H and Nfasc155L (following RIPA extraction), Nfasc155H predominates in the 
brain while similar amounts of the two proteins are extracted from the spinal cord, 
implying unique, tissue-specific levels. 
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Figure 11. Nfasc155H, but not Nfasc155L, requires detergents for extraction from 
brain and spinal cord. RIPA (A.) and PBS (B.) were used to homogenize respective 
halves of the brain and spinal cord from a 5 month old rat. Untreated (-) and PNGase F 
treated (P) lanes are shown. The RIPA homogenized samples indicate 100% of each 
protein and show distinct Nfasc155H and Nfasc155L after treatment with PNGase F. In 
contrast, Nfasc155H is barely detected after PBS homogenization while Nfasc155L is 
comparable between PBS and RIPA. This difference is indicative of Nfasc155L being 
soluble while Nfasc155H likely interacts with other proteins or lipids, resulting in 
insolubility. Panels A and B are the same western blot, optimized for each set of lanes. 
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 * To calculate brain Nfasc155H (units are density values):  
 PBS Nfasc155H   =     325776 
 RIPA Nfasc155H = 23111010 
 RIPA Nfasc155H - 68% = 8782183.8 (corrected RIPA Nfasc155H) 
 (PBS Nfasc155H / corrected RIPA Nfasc155H) * 100 = 3.7% ~ 4% 
 
Nfasc155H exists as both sulfatide-dependent and sulfatide-independent populations 
The data collected thus far regarding Nfasc155H and Nfasc155L indicated that the levels 
of these proteins are altered in the absence of sulfatide and differ in their detergent-
dependent extractabilies. It seemed possible that the detergent-dependent extractabilities 
may vary in a sulfatide-dependent manner. To test this hypothesis, 15 day old WT and 
CST KO mouse spinal cords were homogenized in either RIPA (Figure 12A) or PBS 
(Figure 12B), treated with PNGase F, and band densities compared after western blot. In 
agreement with data already presented (in Figure 9), the RIPA homogenized CST KO 
spinal cords contain approximately 68% less Nfasc155H and 34% less Nfasc155L 
following PNGase F treatment compared to WT. In contrast, the PBS homogenized 
samples contain very similar amounts of both Nfasc155H (100% in WT, 84% in CST KO; 
16% reduced) and Nfasc155L (100% in WT, 88% in CST KO; 12% reduced). A possible 
explanation for the 68% reduction in RIPA versus the 16% reduction in PBS for 
Nfasc155H in the CST KO (a 52% change) is that there are two populations of Nfasc155H 
in WT mice, one that is dramatically decreased in the CST KO (sulfatide-dependent) and 
requires detergents for extraction and another that is minimally decreased in the CST KO  
(sulfatide-independent) and completely extracted in PBS. A similar trend was observed for 
Nfasc155L; however, the difference was much less dramatic. 
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Figure 12. Nfasc155H exists as both sulfatide-dependant and sulfatide-independent 
populations. (A.) As already shown, RIPA homogenization shows an approximately 50% 
reduction in Nfasc155H in the CST KO, compared to WT, while Nfasc155L is minimally 
altered. (B.) In contrast, the WT and CST KO exhibit the same amount of Nfasc155H and 
Nfasc155L when homogenized in PBS, consistent with a sulfatide-dependant population of 
Nfasc155H (altered in the absence of sulfatide, Panel A) and a sulfatide-independent 
population of Nfasc155H (unaltered in the absence of sulfatide, Panel B). 
 - = untreated, P = PNGase F treated 
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Caspr KO mice resemble CST KO mice regarding Nfasc155H and Nfasc155L 
The CST KO mice exhibits altered distribution of Caspr (Ishibashi et al., 2002) and 
Nfasc155 (Marcus et al., 2006). Mice mutated within the Caspr gene (Caspr KO) lack 
Caspr and contactin at the paranode (Bhat et al., 2001) and it was hypothesized that the 
level of Nfasc155H would be disrupted in the Caspr KO mice in a manner similar to the 
CST KO. The spinal cord of a 19 day old Caspr KO and littermate WT were analyzed by 
the same western blot/PNGase F methods previously described for the 15 day old CST KO 
mice already discussed. Figure 13 shows 58% less Nfasc155H and 22% less Nfasc155L in  
the Caspr KO compared to its littermate WT. These reductions strongly resemble those 
observed in the 15 day old CST KO spinal cord. Thus, the substantial decrease of 
Nfasc155H is not specific to an oligodendrocyte defect (CST KO) but appears to be 
universally related to the loss of paranodal integrity. Although the levels of Nfasc155H 
display a greater reduction than Nfasc155L in both the oligodendrocyte (CST KO) and 
neuronal (Caspr KO) mutants, these results do not exclude a role for Nfasc155L as a 
component of the paranode. However, the more severe loss of Nfasc155H in the absence of 
sulfatide and Caspr, combined with the findings presented in Figure 8 that Nfasc155H is a 
component of the paranode, strongly implicate Nfasc155H in the maintenance of paranodal 
stability. 
 
Nfasc155H and Nfasc155L are altered in multiple sclerosis 
As early as 1969 (Suzuki et al.), studies demonstrated that paranodal structure is 
compromised in multiple sclerosis (MS), the most common demyelinating disease of the  
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Figure 13. Caspr KO mice, similar to CST KO mice, exhibit a dramatic reduction in 
Nfasc155H. Spinal cords of 19 day old Caspr KO mice (CPKO) were examined by the 
same PNGase F/extended western protocol already discussed. Similar to the 15 day old 
CST KO mice, the Caspr KO contains approximately 58% less Nfasc155H and 22% less 
Nfasc155L than the littermate WT (CPWT). Following treatment with PNGase F, the 
Caspr KO shows no band representing Nfasc155H, only a diffuse haze (arrow).  
- = untreated, P = PNGase F, MM = Magic Mark Western Protein Standard (Invitrogen) 
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human CNS. It has recently been determined that paranodal integrity is altered in the 
presence of intact nodes (Wolswijk and Balesar, 2003; Howell et al., 2006) in MS tissue. 
Specifically, Caspr spreads out of the paranode and voltage-gated K
+
 channels lose their 
juxtaparanodal confines while Na
+
 channels and Nfasc186 are still observed at the node. 
Since MS demonstrates abnormal protein domain organization reminiscent of the CST and 
Caspr KO mice, it was proposed that Nfasc155H would also be altered in MS. Figure 14 
shows four non MS, four NAWM, and eight MS brain samples run following the same 
parameters used to create Figures 6 and 7A. Qualitatively, Nfasc155H appears as an 
obvious, intense band in each sample while Nfasc155L is visible in two of the MS samples 
(the second one in each set of four) but not observed in any of the non MS or NAWM 
samples. The previously mentioned shadow (Figure 7, 14 - 27 days of age) is seen below 
Nfasc155H in samples from each set, suggesting that Nfasc155L may be present but 
masked, similar to the rat and mouse samples. Accordingly, PNGase F treatment was 
conducted on half of each sample set and the results are presented in Figure 15. None of 
the non MS or NAWM shows distinct Nfasc155L, even after treatment with PNGase F. 
These samples still display the shadow below Nfasc155H, but this cannot be definitively 
called Nfasc155L. The prevalent shadow may be low abundance Nfasc155L but this 
technique does not allow for visualization beyond that which is shown. Figure 15C shows 
a reduced intensity image of the unexpectedly robust sample from Figure 15B. Of note, the 
untreated lane shows only one band, seemingly Nfasc155H, while the PNGase F treated 
lane shows two clear bands, Nfasc155H and Nfasc155L, demonstrating the effectiveness 
of PNGase F treatment in the detection of Nfasc155L. 
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Figure 14. Nfasc155H is present in non MS brain while Nfasc155H and Nfasc155L 
are present in MS brain. A total of four non MS, four NAWM, and eight MS brain 
samples are shown, and while Nfasc155H is present in all samples, Nfasc155L is only 
present in two (denoted   ), both of which are MS samples. The shadow seen below 
Nfasc155H in many of the samples (denoted  ) suggests the masked presence of 
Nfasc155L. MS = multiple sclerosis, NAWM = normal appearing white matter 
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Figure 15. The pattern of Nfasc155H and Nfasc155L is altered in multiple sclerosis. 
(A.) Non MS and NAWM samples do not exhibit Nfasc155L, even after treatment with 
PNGase F, while there is still a shadow below Nfasc155H. (B.) Qualitatively, MS samples 
appear to contain less Nfasc155H than non MS and NAWM samples and Nfasc155L is 
observed in three of the four MS samples evaluated with PNGase F. (C.) One MS sample 
is shown at decreased intensity, revealing that while only one band is seen in the untreated 
lane, both Nfasc155H and Nfasc155L are seen after treatment with PNGase F.  
- = untreated, P = PNGase F treated, MS = multiple sclerosis, NAWM = normal appearing 
white matter 
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 Although non MS spinal cords were not available from the tissue bank, four MS spinal 
cords were received and analyzed by western blot without (Figure 16A) and with PNGase 
F (Figure 16B). Without PNGase F, all four MS spinal cords display both Nfasc155H and 
Nfasc155L. Following treatment with PNGase F, all four MS spinal cords show a higher 
abundance of Nfasc155L than Nfasc155H. The general pattern observed in the MS spinal 
cords strongly resembles the pattern observed in the Caspr KO (Figure 13, smeared 
Nfasc155H with a clear band for Nfasc155L), however, without non MS spinal cord 
samples, the implications remain unclear. 
 
Attempts to identify Nfasc155H and Nfasc155L were not successful 
An important topic that, while addressed, remains unresolved is the amino acid content of 
Nfasc155H and Nfasc155L. It is still not known whether these two proteins are the same 
polypeptide with varying post-translational modifications or two unique polypeptides. 
Mass spectrometry, while not able to provide 100% sequence coverage, could answer this 
question. The following basic strategy was devised to identify the amino acids present in 
Nfasc155H and Nfasc155L with mass spectrometry. IP would allow for isolation of 
neurofascin proteins and these proteins would be separated from each other on a gel and 
visualized with silver stain. Silver stained bands would be cut out of the gel, destained, and 
sent to a mass spectrometry facility for identification. 
 
The efforts presented in Figure 17A show that Nfasc155H and Nfasc155L are present in 
the supernatant of a rat spinal cord before IP, decreased in the supernatant after incubation 
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Figure 16. MS spinal cords contain Nfasc155H and Nfasc155L. (A.) Only MS spinal 
cords were available for examination and all four samples show both Nfasc155H and 
Nfasc155L. (B.) Following treatment with PNGase F, Nfasc155L appears more prevalent 
than Nfasc155H in MS spinal cords. - = untreated, P = PNGase F treated, MS = multiple 
sclerosis 
 
 
 
 
 
 
 
 
 
 
 
 
  
74 
 
 
 
 
 
 
 
 
 
  
75 
with 10 µL of FIGQY primary antibody, and absent from the supernatant after incubation 
with another 20 µL of FIGQY primary antibody. To be clear, this was one supernatant, 
first incubated with 10 µL of antibody, then another 20 µL after realization that Nfasc155H 
and Nfasc155L had been less than 100% captured by IP. 30 µL of antibody was able to 
capture all of the Nfasc155H and Nfasc155L from a one-quarter of the supernatant derived 
from one rat spinal cord. A small fraction of this IP is shown in the fourth lane of the 
western blot in Figure 17A, demonstrating the success of this portion of the project. 
Visualization of this IP on a silver stained gel was also successful, as shown in Figure 17A. 
The intense region labeled “proposed binding complex” was repeatedly observed after IP 
and is possibly comprised of proteins that bind neurofascin proteins. Upon seeing this 
silver stain, it was realized that removal of these proteins from the gel without 
contaminating either protein with trace amounts of the other, thus complicating the mass 
spectrometry, would be impossible. Thus, the PNGase F technique was applied to the IP, 
as shown in Figure 17B. The increased separation of the two proteins provided by PNGase 
F, paired with silver staining should have allowed for confident mass spectrometry of each 
protein. However, none of the mass spectrometry facilities contacted would attempt to 
identify silver stained proteins, even those that had been stained with “mass spectrometry 
compatible silver stain” and destained. The problem, it seemed, was that while silver 
stained proteins are compatible with mass spectrometry, the process requires large amounts 
of protein. Only if the proteins of interest are visible with Coomassie stain are they likely 
to yield a positive result in a mass spectrometer. The main difference between silver stain 
and Coomassie stain is the sensitivity, with silver stain being dramatically more sensitive. 
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To remedy this problem, entire spinal cords from adult rats were harvested and subjected 
to IP with 100 µL of FIGQY, eluted in the buffers required for activity of PNGase F, 
treated with PNGase F, concentrated in Centricon tubes, and visualized. While this gave 
beautiful results on western blots (as per Figure 17B), there simply was not enough 
Nfasc155H or Nfasc155L in one rat spinal cord to be detected by Coomassie. Two sets of 
silver stained Nfasc155H and Nfasc155L was sent to different mass spectrometry facilities, 
but no amino acids were identified. Attempts to run IP on multiple rat spinal cords were 
met with the problem of limited antibody. The FIGQY antibody is not commercially 
available and was supplied to the laboratory in generous, but limited, amounts by Dr. 
Matthew Rasband (Baylor College of Medicine). Several hundred µL were consumed and 
attempts to commit many more hundreds of µL of antibody to this part of the project 
would have prevented every other part of the project from proceeding forward, including 
most of the data presented here. 
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Figure 17. Steps to identify Nfasc155H and Nfasc155L were successfully established, 
but identification did not occur. (A.) The western blot demonstrates the ability of the 
FIGQY antibody to remove Nfasc155H and Nfasc155L from a spinal cord homogenate. 
Increasing the volume of antibody from 10 to 30 µL resulted in complete capture of Nfasc 
proteins in the IP. A small fraction of the IP is shown to demonstrate the effectiveness of 
the protocol. The silver stain shows all of the Nfasc155H and Nfasc155L captured from 
one-quarter of one rat spinal cord homogenate. This was just enough for detection by silver 
stain and later work showed that one whole spinal cord worth of Nfasc155H and 
Nfasc155L was not enough to be detected by Coomassie stain. (B.) PNGase F (P) 
treatment provided further separation of Nfasc155H and Nfasc155L and was intended to 
allow for confident removal of each band from the gel without cross contamination. A 
western blot is shown, demonstrating that the IP and PNGase F protocols work in tandem. 
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{CHAPTER 4 Discussion} 
 
 
Nfasc155H is a component of the myelin paranode 
Nfasc155H has been shown to increase steadily in abundance in the rat spinal cord 
between 7 and 27 days of age, a trend consistent with the major myelin proteins during 
myelination in the rat spinal cord (Yanagisawa et al., 1986). However, Nfasc155H 
abundance decreases between 27 days and 3 months of age while Coetzee and colleagues 
(1998) have shown that myelin protein levels remain constant between 30 and 90 days of 
age, suggesting that Nfasc155H may play variable roles in myelination and myelin 
maintenance. Additionally, it has been shown here that Nfasc155H localizes to the 
paranode in the spinal cord of a 7 day old rat, consistent with Tait and colleagues (2000) 
who showed, with immunoelectron microscopy, that the NFC1 antibody (shown here in 
Figure 6B) labels the point of contact between the paranodal loops of myelin and the axon. 
Nfasc155 has been previously shown to be expressed only by oligodendrocytes (Collinson 
et al., 1998) and it is therefore concluded that Nfasc155H is an oligodendrocyte-specific 
protein and a component of the myelin paranode. 
 
Nfasc155L as a myelin component 
Nfasc155L is first detected on a western blot by 14 days of age in the rat spinal cord then 
gradually increases in abundance up to 5 months of age and is more abundant than 
Nfasc155H at 3 and 5 months of age. The lack of Nfasc155L-specific antibodies is a 
hindrance to the identification of the cell of origin and location of Nfasc155L; however, 
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inferences can be made based on the data presented here. Figure 11A shows that there is 
more Nfasc155L in 25 µg of spinal cord homogenate than in 40 µg of brain homogenate, 
demonstrating white matter-enrichment for Nfasc155L. Additionally, published (Marcus et 
al., 2006) and unpublished (Shepherd et al., manuscript in progress) observations from this 
laboratory reveal that the thickness of the myelin sheath increases throughout life, resulting 
in paranodal loops that form stacks above the traditional paranode and do not contact the 
axon. The increasing abundance and white matter-enrichment of Nfasc155L combined 
with the increasing thickness of myelin and number of paranodal loops through life is 
consistent with a role for Nfasc155L in the maintenance of mature myelin sheaths. 
Nfasc186 (Davis et al., 1993) and Nfasc155 (Gollan et al., 2003) have each been shown to 
bind homophilically in trans, consistent with the hypothesis that Nfasc155L maintains 
homophilic interactions across (in trans) lamellae in the same myelin sheath and 
suggesting a reason for the increasing abundance of Nfasc155L with age. Specifically, as 
myelin becomes thicker and thicker with age, Nfasc155L expression may be up regulated 
to aid in maintaining the stability of successive lamellae in the absence of axonal contact. It 
is therefore proposed that Nfasc155L is a highly glycosylated transmembrane protein and a 
component of the myelin sheath involved in myelin:myelin cohesion. Similarly, the Ig 
Superfamily member myelin-associated glycoprotein (MAG), is located at various points 
in the myelin sheath and expressed as two alternatively spliced, similarly sized, 
developmentally variable isoforms (Trapp et al., 1989) with no known in vivo binding 
partners; however see Shelke et al., 2007.  
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Nfasc155H and Nfasc155L are differentially glycosylated 
Treatment of homogenates from animals over one month of age (when both Nfasc155H 
and Nfasc155L are clearly visible) with PNGase F results in shifts of 12 and 17 kDa for 
Nfasc155H and Nfasc155L, respectively. Based on each site representing approximately 
2.5 kDa, these shifts are consistent with the NetNGlyc Server 1.0 prediction for rat 
Nfasc155, which predicts five highly likely and two somewhat likely sites of N-linked 
glycosylation (see Materials and Methods for definitions). Furthermore, this difference in 
N-linked glycosylation suggests either a protein domain unique to Nfasc155L or distinct 
glycosylation of Nfasc155H and Nfasc155L, perhaps due to different cellular or 
subcellular localizations. Since both proteins are visible as distinct bands before and after 
PNGase F treatment (did not collapse into one band), they likely differ in either another 
post-translational modification and/or amino acid content. 
 
Nfasc155L is alternatively glycosylated with age 
Experiments with PNGase F demonstrate that Nfasc155L is present in WT rat spinal cords 
as young as 14 days of age, while Nfasc155L is not observed until 3 months of age in 
untreated samples. In these untreated samples, Nfasc155L seems to gradually form from 
the shadow below Nfasc155H between 14 and 27 days of age (Figure 7), suggesting that 
Nfasc155L becomes alternatively glycosylated with age, causing it to migrate with 
Nfasc155H in young animals and lower than Nfasc155H in older animals. Supportive of 
this idea, both Nfasc155H and Nfasc155L shift following treatment with PNGase F, with 
Nfasc155L more so than Nfasc155H at older ages (over 30 days of age) while the shift is 
  
82 
not measurable in younger animals due to the undefined location of Nfasc155L in non-
PNGase F treated young samples. Presumably, Nfasc155L is migrating at almost exactly 
the same rate as Nfasc155H in young animals (day 14), and an extrapolation can be made 
that the shift from untreated Nfasc155H+L to PNGase treated Nfasc155L is 22 kDa. This 
is 5 kDa more than the 17 kDa shift reported here for Nfasc155L in older animals, 
indicative of approximately two more sites of N-linked glycosylation for Nfasc155L in 
younger (14 - 30 days old) compared to older animals. It is reasonable to believe that 
Nfasc155L gradually loses two N-linked glycosylations with age, accounting for the 
increasingly dark shadow below Nfasc155H that gives rise to distinct Nfasc155L at 3 
months of age. Alternative glycosylation of proteins in the context of cellular maturation 
has been previously demonstrated for Ig Superfamily members in the immune system 
(reviewed by Daniels et al., 2002). This alternative glycosylation with age may be 
involved in the proposed trans homophilic interactions of Nfasc155L. CST KO mice 
appear to properly follow this age-dependent change in glycosylation, with Nfasc155L 
being present and in approximately normal amounts at all ages examined. 
 
Is the specific reduction of Nfasc155H in paranodal mutants due to improper 
interactions at the myelin paranode? 
Analysis with PNGase F reveals that sulfatide null spinal cords contain ~50% less 
Nfasc155H than littermate WT at 15 days and 30 days and nearly 100% less at 4 months of 
age (Figure 9). Similarly, Nfasc155H is reduced ~70% in the spinal cord of the 19 day old 
Caspr KO mouse. In both CST and Caspr KO spinal cords, Nfasc155L content is 
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minimally altered. Since evidence presented here strongly indicates that Nfasc155H is a 
paranodal component, the near complete loss of Nfasc155H by 4 months of age likely 
explains the near complete loss of anti-Nfasc reactive paranodes in older CST KO mice 
(Figure 4C, Marcus et al., 2006).  
 
In addition to the immunohistochemistry presented in Marcus et al. (2006), this laboratory 
has since quantified paired paranodal clusters at 15 and 30 days (Pomicter et al., 
manuscript in progress). Compared to littermate WT, CST KO spinal cords contain ~50% 
and 90% fewer paired paranodal clusters (defined by reactivity with the NFC1 antibody) at 
15 and 30 days of age, respectively. It is interesting to note that paired paranodal clusters 
are not simply altered in the absence of sulfatide; they are increasingly altered in the 
absence of sulfatide. The results of the western blot in Figure 9 shows that Nfasc155H is 
reduced ~50% at both ages, indicating that the 90% reduction in paired clusters observed at 
30 days of age is likely due to improperly localized, and therefore undetectable, 
Nfasc155H. This demonstrates that even in the presence of Nfasc155H, paired paranodal 
clusters are formed but not maintained in the absence of sulfatide. 
 
The CNS of the CST KO mouse contains normal amounts of mRNA for PLPs, MBPs, and 
MAGs (Honke et al., 2002) as well as normal amounts of proteins for MBPs, and CNPs 
(presented here) at various ages, strongly suggesting that transcription and translation are 
unaltered in oligodendrocytes by the absence of sulfatide. If the transcription and 
translation of Nfasc155H are also unaltered in the CST KO, then protein stability could 
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account for the reduction in Nfasc155H at each age examined; leading to the question, 
“Why is only Nfasc155H reduced in the absence of sulfatide?”. 
 
A leading explanation can be drawn from comparisons between PBS and RIPA 
homogenized tissue, which demonstrates that Nfasc155L is extracted in the absence of 
detergent. This is consistent with Nfasc155H being the protein studied by Schafer and 
colleagues (2004) since fractionation based on solubility was their first step and the high 
solubility of Nfasc155L (shown here) excludes it from their study. The authors describe 
Nfasc155 as having characteristics consistent with lipid raft/membrane microdomain 
incorporation and it is proposed here that they were examining only Nfasc155H. This may 
help to explain why Nfasc155H is so dramatically altered in the sulfatide null mice. 
Arvanitis and colleagues (2005) have shown that sulfatide (cerebroside sulfate) is enriched 
in a specific fraction of isolated myelin that also contains enrichments of the lipid raft 
proteins fyn (Krämer et al., 1999), flotillin-1 (Salzer et al., 2001), and caveolin 
(Sargiacomo et al., 1993). This enrichment demonstrates a relationship between sulfatide 
in myelin and specific membrane microdomain-associated proteins, with Nfasc155H at the 
myelin paranode seemingly being one of them. Loss of sulfatide will compromise this 
interaction, allowing for altered localization (as shown by Marcus et al., 2006, see Figure 
3C), loss of any/all intracellular/extracellular binding, and perhaps eventual degradation of 
Nfasc155H.  
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Similarly, in the absence of Caspr, the amounts of PLPs, MBPs, and contactin proteins are 
unaltered (Bhat et al., 2001). The Caspr KO mouse shows no band representing 
Nfasc155H at 19 days of age (Figure 13), suggesting that Nfasc155H is either not 
transcribed/translated or abnormally degraded in the absence of its trans binding complex. 
Since it is unlikely that Caspr regulates the transcription/translation of Nfasc155H (the two 
proteins being transmembrane and in different cells) and since other myelin proteins are 
translated normally, the implication is that Nfasc155H is abnormally maintained in the 
absence of Caspr. Altered interactions at the paranode may then result in exposure to 
degradative pathways not normally accessible to Nfasc155H, similar to what has been 
proposed in the absence of sulfatide. 
 
Nfasc155H and Nfasc155L likely differ in amino acid content 
Nfasc155H and Nfasc155L differ by ~10 kDa following removal of N-linked 
carbohydrates; a difference not easily accounted for by other post-translational 
modifications. Phosphorylation, the most widely studied post-translation modification 
(Sims and Reinberg, 2008), for example, has been described as a predominantly 
intracellular modification and results in minimal changes in the apparent molecular mass of 
a protein. Specifically, 13 phosphate groups (~95 Daltons each) on a 25 kDa protein 
changes the apparent size by less than 3 kDa (Gingras et al., 1998). The Nfasc cytoplasmic 
domain is comprised of less than 130 amino acids and contains only ~20 total serines, 
threonines, and tyrosines (Davis et al., 1993), whereas ~44 phosphorylations would be 
required to constitute 10 kDa (3 kDa/13 sites = 0.23 kDa/site; 10 kDa/(0.23 kDa/site) = 44 
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sites). This does not, however, rule out phosphorylation as a contributor to the size 
difference, and Nfasc155 has been indirectly suggested to be phosphorylated at one 
intracellular site (Garver et al., 1997; Jenkins et al., 2001). 
 
A recently discovered post-translational modification is the addition of the peptide named 
small ubiquitin-like modifier and known as SUMO. The addition of a SUMO is termed 
SUMOylation and is the addition of a 10 kDa (Braun et al., 2008) peptide to a lysine in the 
following sequon: large hydrophobic amino acid, lysine, any amino acid, glutamic acid. 
This modification has been shown to be mostly involved in chromatin organization, 
transcription, and RNA metabolism (reviewed by Hay, 2005) and, while the size fits the 
difference between Nfasc155H and Nfasc155L, the functions prescribed to SUMOylated 
proteins do not fit any of the known functions for Ig Superfamily proteins (Salzer, 1995). 
 
Other potential post-translational modifications that might account for or contribute to the 
10 kDa difference observed between Nfasc155H and Nfasc155L following removal of N-
linked carbohydrates with PNGase F are similar to phosphorylation in that they do not add 
enough mass to the peptide to make a shift observable on a western blot unless dozens of 
groups are added. This includes methylation (~15 Daltons), sulfation (~96 Daltons), 
acetylation (~43 Daltons), and various lipid additions (palmitic acid is ~256 Daltons and 
myristic acid is ~228 Daltons). The contribution of charged post-translational 
modifications to gel migration is difficult to account for, but as shown for negatively 
charged phosphorylation, requires numerous sites to change the apparent molecular mass 
  
87 
of a protein. 
 
Additionally, while mass spectrometry did not provide information regarding specific 
peptides present in Nfasc155H and Nfasc155L, detailed analyses of the results presented in 
this thesis provide evidence to suggest that protein domain content accounts for the 
difference between the two proteins. Nfasc186 appears unaltered in the absence of 
sulfatide at all ages evaluated and was not the focus of this study. Nonetheless, data 
regarding Nfasc186 has been accumulated due to the shared cytoplasmic domain targeted 
by the NFC1 and FIGQY antibodies. Of this data, the most interesting point is that 
Nfasc186 shifts only 9 kDa following PNGase F treatment, making Nfasc155H and 
Nfasc186 ~30 kDa different in apparent molecular mass after the removal of N-linked 
carbohydrates. What then accounts for the difference in the apparent molecular masses of 
Nfasc155H and Nfasc186? As previously stated, Nfasc155 and Nfasc186 differ in protein 
domain make up regarding the three insert domains, the 3
rd
 FNIII domain (Nfasc155 only), 
and the mucin-like/PAT domain (Nfasc186 only). Calculations with the ExPASy Compute 
pI/MW tool show that Nfasc155 and Nfasc186 differ by no more than 8 kDa, with 
Nfasc186 being more massive. Evaluation of this apparent discrepancy points toward the 
5
th
 FNIII (10.2 kDa) domain being present in Nfasc186. Recall that this domain exists in 
the Nfasc gene and has been observed in cDNA (Hassel et al., 1997) but that its presence 
in Nfasc proteins has never been evaluated. Additionally, other L1 subfamily members, 
including L1 and NrCAM, contain a 5
th
 FNIII domain (Hassel et al., 1997). Analysis of the 
5
th
 FNIII domain with the NetNGlyc 1.0 Server predicts three sites of N-linked 
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glycosylation (more than any other Nfasc domain), including one somewhat likely, one 
highly likely, and one extremely likely site of N-linked glycosylation (the only extremely 
likely site in all of the possible Nfasc domains, 9/9 neural networks agree, + + + score). 
The mucin-like/PAT domain of Nfasc186 is predicted to be rich in O-linked glycosylation 
but this has been shown to be a minor contributor to the apparent molecular mass of 
Nfasc186 (Volkmer et al., 1992). Thus, the inclusion of an alternatively glycosylated 5
th
 
FNIII domain in Nfasc186 is a leading contender to partially account for the difference in 
apparent molecular mass between Nfasc186 and Nfasc155H, consistent with Koticha and 
colleagues (2005).  
 
These ideas contribute to the evaluation of the potential differences between Nfasc155H 
and Nfasc155L. It has been proposed here that Nfasc155L is N-glycosylated at more sites 
than Nfasc155H in older animals and at even more sites in younger animals. The 
knowledge that the exons encoding the 5
th
 FNIII domain are alternatively spliced and 
contain three possible sites for N-linked glycosylation immediately implicates it as a 
possible component of Nfasc155L that is lacking in Nfasc155H. While all of the other 
FNIII domains of L1 subfamily members are encoded by a pair of exons, the 5
th
 FNIII 
domain of Nfasc has been observed in cDNAs as a half domain (Hassel et al., 1997), with 
the first exon being the more commonly expressed half and encoding two predicted sites of 
N-linked glycosylation. Additionally, Nfasc Ig-like domains are alternatively spliced much 
less frequently than are FNIII domains, with all six Ig-like domains being present in over 
half of the cDNA clones examined in the study of clones from embryonic days 6 and 16 by 
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Hassel and colleagues (1997). 
 
While no definitive statements can be made, it is conceivable that Nfasc 155L contains the 
5
th
 FNIII domain and lacks the 3
rd
 FNIII domain, which is also highly alternatively spliced 
(Hassel et al., 1997) and contains only one predicted site of N-linked glycosylation (8/9 
neural networks agree, + score; somewhat likely). This alternative exon usage may account 
for the differences in N-linked glycosylation observed between Nfasc155H and 
Nfasc155L, however exchange of the 3
rd
 FNIII domain (12.3 kDa) for the 5
th
 FNIII domain 
(10.2 kDa) only accounts 2.1 kDa. Since it has been shown here that Nfasc155H and 
Nfasc155L differ by 10 kDa after treatment with PNGase F, the remaining ~8 kDa could 
be accounted for by alternative usage of the highly alternatively spliced insert domains, 
calculated to be between 0.6 and 2.1 kDa each. Additional size variability may come from 
post-natal-specific alternative splicing of FNIII domains 1, 2, and 4 (10-12 kDa each) as 
well as each half domain of the 5
th
 FNIII (4.6 and 5.7 kDa, respectively) that would not 
have been observed in the embryonic study of Hassel and colleagues (1997) and consistent 
with the initial expression of Nfasc155L between post-natal days 7 and 14. 
 
Nfasc155H and Nfasc155L levels are altered in multiple sclerosis 
The alterations regarding MS tissue indicate that while abundant Nfasc155L is not 
normally observed in human brain, it can become more prevalent in MS plaques. 
Concurrently, Nfasc155H appears to be lost in these same plaques insinuating that 
Nfasc155L forms from Nfasc155H under pathological mechanisms, but this does not 
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appear to be the case in either rats or mice. Resolution of this apparent conflict will require 
detailed studies with large sample sizes and immunohistochemical studies to define the 
disease status of each piece of tissue paired with western blots to distinguish Nfasc155H 
and Nfasc155L. 
 
Two categories of possible scenarios exist; either rodents and humans follow the same 
mechanisms regarding expression and maintenance of Nfasc155H and Nfasc155L and ones 
where they differ. Considering that they are the same, rodents exhibit gradually increasing 
amounts Nfasc155L with age while Nfasc155H peaks near 30 days of age, drops sharply 
by 3 months, and is maintained until at least 5 months of age, such that Nfasc155L is the 
predominant form at 3 and 5 months of age. Predominant Nfasc155L is only observed in 
human tissue in the case of MS, however, Nfasc155L levels in human development have 
not been analyzed. Perhaps humans express barely detectable amounts Nfasc155L, but 
with the same function as rodent Nfasc155L, and the demyelination:remyelination 
occurrences of MS result in aberrant expression of myelin-related genes, resulting in 
elevated levels of Nfasc155L. 
 
Considering that rodents and humans differ with regards to Nfasc155H and Nfasc155L, 
rodent and (likely) human Nfasc155H is a myelin paranode concentrated protein involved 
in cell adhesion. Rodent Nfasc155L appears to be involved in a process or processes that 
become more common in older animals. Unpublished observations from this laboratory 
have led to the supposition that rodent Nfasc155L could be involved in myelin compaction 
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via myelin:myelin adhesion, an idea consistent with observed ever-increasing numbers of 
paranodal loops, presumed to be additional wraps of myelin, as the animals age. Perhaps 
humans have another protein that fulfills this purpose, or the actual purpose of Nfasc155L, 
such that it is only expressed by humans as needed, and the demyelination:remyelination 
occurrences indicative of MS activate emergency myelin-related pathways involving 
Nfasc155L. Also, since rodent Nfasc155L has been shown to be differentially glycosylated 
with age, it is conceivable that human Nfasc155L is glycosylated such that it migrates 
along with Nfasc155H through life and that this glycosylation state is altered in MS, 
allowing for visualization of Nfasc155L. This idea is supported by the first sample in 
Figure 11B and by Figure 11C where the untreated samples contain one band and the 
PNGase F treated samples contain two bands (Nfasc155H and Nfasc155L).  
 
Establishing the extended western blot protocol 
Western blotting has become a technique so common that every lab has its own protocols 
and modifications. The technique used here to visualize the proteins of interest is one that 
has been optimized based on knowledge acquired while troubleshooting the original 
technique. While most protocols call for no particular percentage of gel, one hour of gel 
electrophoresis, and one hour of electrophoretic transfer, the protocol developed in this 
project uses 10% Ready Gels, three hours of gel electrophoresis, and two hours of 
electrophoretic transfer. The details of why this is the optimal protocol follows. 
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The proteins of interest in this project migrate slightly slower than the 150 kDa molecular 
weight standard (Kaleidoscope Ladder, Bio-Rad). As discussed earlier, Nfasc186 and 
Nfasc155 are recognized by the same pan-neurofascin antibodies and both proteins are 
seen on a western blot if these antibodies are applied. Separating these two protein bands 
from each other is a fairly simple task; however, caution must be taken to be sure that a gel 
is run long enough to allow for visualization of two distinct bands. In early efforts to do 
just this, it became clear that the band originally assigned as Nfasc155 migrates as two 
bands (Nfasc155H and Nfasc155L) when electrophoresis is extended beyond one hour. 
Attempts to study this novel finding led to gels being run for longer and longer times to 
allow the two new bands to be clearly distinguished from one another. Whereas one hour 
of electrophoresis revealed only Nfasc186 and Nfasc155, two hours of electrophoresis 
resulted in the Nfasc155 band dividing into two but the bands remained close enough to 
each other that they touched. Three hours of electrophoresis resolved this problem and 
made Nfasc186, Nfasc155H, and Nfasc155L clearly visible and distinct from one another. 
In the end, gels were run at 70 volts for 20-30 minutes to allow for protein stacking then at 
150 volts until the 75 kDa ladder band reached the bottom of the gel (approximately 
another two and one half hours). This made for another problem, however, since most 
loading/transfer control proteins are below 50 kDa; ERK2 and β-actin migrate at 
approximately 42 kDa. To overcome this, a second western blot was performed on the day 
after the Nfasc one and run for only one hour after protein stacking with a one hour 
transfer. 
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At the same time, one hour of electrophoretic transfer at 100 Volts was observed to leave 
some of the high molecular weight Kaleidoscope ladder bands in the gel, demonstrating 
less than 100% efficiency in the transfer of large proteins. Proteins below 100 kDa were no 
longer visible in the gel after transfer while proteins 100 kDa and above were visible on the 
nitrocellulose membrane and in the gel. Increasing the transfer time from one hour to two 
hours and keeping the voltage at 100 resolved this problem (and showed more distinct 
Nfasc bands) but increased the amount of heat generated by the power supply. To 
overcome the heat of one hour of transfer, most protocols call for the transfer apparatus to 
be placed in a cooler that is then filled with ice water. Not mentioned in most protocols, 
but utilized in many laboratories, is the addition of an ice-filled chamber inside the transfer 
apparatus. Early troubles in perfecting this protocol came from not properly cooling the 
transfer apparatus during the one hour transfer. Upon realizing that a two hour transfer 
would be beneficial yet dangerously hot to the gel and/or membrane, transfers were carried 
out in a large plastic container (roughly five times the volume of the transfer apparatus) 
filled with ice  water. This was sufficient to keep the transfer buffer, and presumably the 
gel sandwich, cold throughout the transfer. Refreshing the internal ice chamber after one 
hour of transfer aided in cooling.  
 
Gradient gels work well for experiments involving two-three proteins when those proteins 
are notably different in size, 30 and 120 kDa for example. The higher concentration of 
acrylamide (the essence of the “gel”) near the bottom of the gel prevents smaller proteins 
from exiting the gel. For visualization of only Nfasc186 and Nfasc155, almost any 
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percentage gel will work. As the novel banding pattern became more interesting, it was 
apparent that special considerations regarding the gel percentage would be needed. 
Gradient gels were utilized at this time in the laboratory but showed variable results. Early 
advice on how to optimally separate these two bands pointed toward 7.5% gels being ideal 
for the separation of larger proteins. While true, these gels are too weak to survive the 
harsh conditions that a gel will undergo during an extended run and a two hour transfer. 
The heat, pressure, and/or contact involved in blotting causes 7.5% gels to stick to the gel 
sandwich and become unusable. The next best attempt is 10% gels, which allowed for 
separation of all the proteins of interest and survive transfer. 
 
Concluding Remarks 
The developmentally variable presence of Nfasc155H and Nfasc155L may provide clues to 
some of the contradictory results presented in the literature (Charles et al., 2002; Bonnon 
et al., 2003; Gollan et al., 2003) regarding the requirements for contactin:Caspr:Nfasc155 
interactions. It is conceivable that certain investigators were studying only Nfasc155H or 
only Nfasc155L while other investigators were studying both simultaneously but were 
unaware of this since Nfasc155H and Nfasc155L migrate together on gels when examining 
homogenates of younger animals. Additionally, the variable glycosylation presented here 
between Nfasc155H and Nfasc155L, as well as the variable glycosylation between young 
and old animal-derived Nfasc155L, may play a role in interactions with these proteins, 
comparable to those observed for contactin and Caspr (Gollan et al., 2003). Further 
understanding of the exact compositions of Nfasc155H and Nfasc155L will allow for 
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evaluative binding studies and will continue adding to the understanding of the formation 
and stability of the paranode and axon functional domains. 
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